Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study was to evaluate the safety and tolerability and to determine the recommended phase 2 dose (RP2D) and/or the maximum tolerated dose (MTD) of ASP7517.
This study also evaluated the clinical response of ASP7517 as well as other measures of anticancer activity of ASP7517.
This study consisted of 2 parts: phase 1 dose escalation and phase 2 dose expansion.
Phase 1 Dose Escalation:
Approximately 18 subjects with either relapsed/refractory (R/R) AML or R/R higher risk MDS were enrolled. Participants received 2 single doses of ASP7517 via intravenous infusion. Dosing occured on day 1 of each cycle. Each cycle was defined as 28 days with a total of 2 treatment cycles.
Participants were managed under hospitalization for at least 7 days during the first cycle of the dose escalation phase. In addition, prior to hospital discharge, participant safety was ensured by performing medical tests and procedures listed on day 7 of cycle 1 and tests considered clinically necessary to evaluate the participant's general condition and adverse event (AE) resolution. The participant was also followed on an outpatient basis on planned visits during cycles 1 and 2 after hospital discharge during the dose limiting toxicity (DLT) assessment period to closely monitor any AEs. Participants were hospitalized days 1 to 7 during cycle 2.
Phase 2 Dose Expansion:
Approximately 104 participants per dose level were enrolled. Each dose level enrolled up to 52 R/R AML participants and up to 52 R/R higher risk MDS participants. Both groups of participants were enrolled in parallel and independently. The number of dose levels investigated during phase 2 were based upon the data from phase 1. When escalation and expansion cohorts were both open for enrollment, enrollment into escalation cohorts took priority such that participants who were eligible for both were preferentially enrolled in the escalation cohorts.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Dose Escalation (Phase 1): ASP7517 1x10^6 cells/mL | Experimental | Participants with Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) and R/R higher risk Myelodysplastic Syndrome (MDS) received intravenous (IV) infusion of ASP7517 (human embryonic kidney cell [HEK293] transfected with encoding target WT-1) at a dose of 1x10^6 cells/milliliters (mL) at 4 to 6 mL/minute infusion rate on day 1 of each cycle for 2 doses (1 cycle= 28 days). |
|
| Dose Escalation (Phase 1): ASP7517 1x10^7 cells/mL | Experimental | Participants with R/R AML and R/R higher risk MDS received IV infusion of ASP7517 (HEK293 transfected with encoding target WT-1) at a dose of 1x10^7 cells/mL at 4 to 6 mL/minute infusion rate on day 1 of each cycle for 2 doses (1 cycle= 28 days). |
|
| Dose Escalation (Phase 1): ASP7517 1x10^8 cells/mL | Experimental | Participants with R/R AML and R/R higher risk MDS received IV infusion of ASP7517 (HEK293 transfected with encoding target WT-1) at a dose of 1x10^8 cells/mL at 4 to 6 mL/minute infusion rate on day 1 of each cycle for 2 doses (1 cycle= 28 days). |
|
| Dose Expansion (Phase 2: AML): ASP7517 1x10^8 cells/mL | Experimental | Participants with R/R AML received IV infusion of ASP7517 (HEK293 transfected with encoding target WT-1) at a dose of 1x10^8 cells/mL at 4 to 6 mL/minute infusion rate on day 1 of each cycle for 6 doses (1 cycle= 28 days). |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| ASP7517 | Biological | Intravenous (IV) |
|
| Measure | Description | Time Frame |
|---|---|---|
| Number of Participants With Dose Limiting Toxicities (DLTs) | DLT was defined as any of the following events that occurred within 28 days starting with the first dose on cycle 1 day 1 (C1D1) and that was considered to be related to study drug. DLT was defined as follows:
| Day 1 up to 28 days |
| Number of Participants With Treatment Emergent Adverse Events (TEAE) & Serious TEAE | An AE was defined as any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE could therefore be any unfavorable & unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. An AE was considered "serious" if, it resulted in any of the following outcomes: results in death; is life-threatening; results in persistent or significant disability/incapacity or substantial disruption of the ability to conduct normal life functions; results in congenital anomaly, or birth defect; requires inpatient hospitalization; or leads to prolongation of hospitalization; other medically important events. TEAE was defined as an AE observed after starting administration of the study drug. TEAEs included both Serious and non-serious AEs. | From first dose up to 43 months |
| Phase 2: Composite Complete Remission (CRc) Rate for Participants With R/R AML | Percentage of participants with CRc was reported. CRc:defined as rate of all complete & incomplete remissions (CR + CR with incomplete platelet recovery [CRp] + CR with incomplete hematological recover [Cri]). CR: achieved morphologic leukemia-free state & their bone marrow was regenerating normal hematopoietic cells. If absolute neutrophil count (ANC) ≥ 1×10^9/L, platelet count (PC) ≥ 100×10^9/L, normal marrow differential < 5% blasts, & were red blood cell (RBC) and platelet transfusion independent (defined as 1 week without RBC transfusion & platelet transfusion prior to disease assessment). There was no evidence of extramedullary leukemia or Auer rods & blast counts in peripheral blood must be ≤ 2%. CRp: must achieve CR except for incomplete platelet recovery (< 100×10^9/L). CRi: must fulfil CR except for incomplete hematological recovery with residual neutropenia (ANC < 1×10^9/L), with or without complete platelet recovery. RBC and platelet transfusion independence not required. |
| Measure | Description | Time Frame |
|---|---|---|
| Duration of Remission (DR) for Participants With R/R AML | DR for AML: included duration of CRc, duration of CR/complete remission with partial hematologic recovery (CRh), duration of CRh, duration of CR, and duration of response (i.e., CRc + PR). CRh: achieved marrow blasts < 5%, partial hematologic recovery ANC ≥ 0.5 × 10^9/L and platelets ≥ 50 × 10^9/L, no evidence of extramedullary leukemia and cannot be classified as CR. The blast counts in peripheral blood was ≤ 2%. PR for AML; achieved bone marrow regenerating normal hematopoietic cells with evidence of peripheral recovery with no (or only a few regenerating) circulating blasts with decrease of at least 50% in the percentage of blasts in bone marrow aspirate with total marrow blasts between 5% and 25%. Value ≤ 5% blasts was considered PR if Auer rods were present. No evidence of extramedullary leukemia. CR, CRc were defined in outcome measure #3. Kaplan Meier (KM) Estimate was used. |
Not provided
Inclusion Criteria:
Subject diagnosed with R/R AML or R/R higher risk MDS is defined as:
Subject has an Eastern Cooperative Oncology Group performance status of ≤ 2.
Subject must meet the following criteria as indicated on the clinical laboratory tests during screening period:
Subject has a life expectancy of ≥ 12 weeks at the time of screening.
Subjects with AML must have peripheral blood absolute blast count of < 20,000/μL at C1D1. Note: Blast count can be controlled by hydroxyurea during screening period.
Female subject is not pregnant and at least 1 of the following conditions apply:
Female subject must agree not to breastfeed starting at screening and throughout the study period and for 180 days after the final study treatment administration.
Female subject must not donate ova starting at first dose of investigational product (IP) and throughout the study period and for 180 days after final study treatment administration.
Male subject with female partner(s) of childbearing potential (including breastfeeding partner) must agree to use contraception throughout the treatment period and for 180 day after final study treatment administration.
Male subject must not donate sperm during the treatment period and for 180 days after the final study treatment administration.
Male subject with pregnant partner(s) must agree to remain abstinent or use a condom for the duration of the pregnancy throughout the study period and for 180 days after final study treatment administration.
Subject agrees not to participate in another interventional study while receiving study treatment in the present study.
Exclusion Criteria:
Subject was diagnosed with acute promyelocytic leukemia.
Subject has breakpoint cluster region-Abelson-positive leukemia (BCR-ABL).
Subject has persistent non-hematological toxicities of ≥ grade 2 (National Cancer Institute's Common Terminology Criteria for Adverse Events [NCI-CTCAE], version 5.0), with symptoms and objective findings from prior AML or MDS treatment (including chemotherapy, kinase inhibitors, immunotherapy, experimental agents, radiation or surgery).
Subject has received any of the following therapies:
Subject has clinically active nervous system leukemia.
Subject has active or prior documented autoimmune or inflammatory disorders requiring systemic treatment.
Subject has ongoing, untreated malignancy with the exception of the following:
Subject with left ventricular ejection fraction of < 45% on echocardiogram or multigated acquisition scan (MUGA) performed within 28 days of screening.
Subject has laboratory abnormalities, or clinical evidence of disseminated intravascular coagulation, or ongoing history of coagulation disorder manifested by bleeding or clotting.
Subject has an active uncontrolled infection.
Subject is known to have human immunodeficiency virus infection.
Subject has active hepatitis B or C or other active hepatic disorder.
Subject has any condition which makes the subject unsuitable for study participation.
Subject has a known or suspected hypersensitivity to bovine-derived protein or has suspected hypersensitivity to any ingredients of ASP7517.
Subject is eligible for HSCT.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Medical Director | Astellas Pharma Global Development, Inc. | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| City of Hope | Duarte | California | 91010 | United States | ||
| Memorial Healthcare System-West |
Not provided
| Label | URL |
|---|---|
| Link to plain language summary of the study on the Trial Results Summaries website. | View source |
| Link to results and other applicable study documents on the Astellas Clinical Trials website. | View source |
Not provided
Access to anonymized individual participant level data will not be provided for this trial. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.
Not provided
Not provided
Not provided
Not provided
Participants who met all inclusion criteria and none of the exclusion criteria were enrolled in the study.
Participants with relapsed/refractory acute myeloid leukemia and relapsed/refractory higher risk myelodysplastic syndrome were enrolled in the study.
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Dose Escalation (Phase 1): ASP7517 1x10^6 Cells/mL | Participants with Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) and R/R higher risk Myelodysplastic Syndrome (MDS) received intravenous (IV) infusion of ASP7517 (human embryonic kidney cell [HEK293] transfected with encoding target WT-1) at a dose of 1x10^6 cells/milliliters (mL) at 4 to 6 mL/minute infusion rate on day 1 of each cycle for 2 doses (1 cycle= 28 days). |
| Title | Milestones | Reasons Not Completed | |||||
|---|---|---|---|---|---|---|---|
| Dose Escalation Phase (56 Days) |
|
Not provided
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot | Yes | No | No | Study Protocol | Sep 19, 2022 | Apr 12, 2024 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Dose Expansion (Phase 2: MDS): ASP7517 1x10^8 cells/mL | Experimental | Participants with R/R higher risk MDS received IV infusion of ASP7517 (HEK293 transfected with encoding target WT-1) at a dose of 1x10^8 cells/mL at 4 to 6 mL/minute infusion rate on day 1 of each cycle for 6 doses (1 cycle= 28 days). |
|
| From first dose up to 43 months |
| Phase 2: Complete Remission + Bone Marrow Complete Remission + Partial Remission (CR + BM CR + PR) Rate for Participants With R/R Higher Risk MDS | Percentage of participants with CR+BM CR+ PR was reported. CR, BM CR and PR achieved for minimum of 4 weeks; CR: bone marrow: ≤ 5% myeloblasts with normal maturation of all cell Lines, peripheral blood evaluation (hemoglobin (Hb) ≥ 11 g/dL, platelets ≥ 100 × 10^9/L, neutrophils ≥ 1.0 × 10^9/L, 0% blasts in blood) BM CR: bone marrow: ≤ 5% myeloblasts and decrease by ≥ 50% over pretreatment PR: achieved all CR criteria except bone marrow blasts decreased by ≥ 50% over pretreatment but still > 5%, cellularity and morphology not relevant. | From first dose up to 43 months |
| Number of Participants With ECOG Performance Status at Cycle 1(C1) Day2(D2) | Number of participants with ECOG PS was reported. ECOG performance status was measured on a 6 point grade scale. 0: Fully active, able to carry on all pre-disease performance without restriction.
| C1D2 |
| Number of Participants With ECOG Performance Status at C1D4 | Number of participants with ECOG PS was reported. ECOG performance status was measured on a 6 point grade scale. 0: Fully active, able to carry on all pre-disease performance without restriction.
| C1D4 |
| Number of Participants With ECOG Performance Status at C1D8 | Number of participants with ECOG PS was reported. ECOG performance status was measured on a 6 point grade scale. 0: Fully active, able to carry on all pre-disease performance without restriction.
| C1D8 |
| Number of Participants With ECOG Performance Status at C1D11 | Number of participants with ECOG PS was reported. ECOG performance status was measured on a 6 point grade scale. 0: Fully active, able to carry on all pre-disease performance without restriction.
| C1D11 |
| Number of Participants With ECOG Performance Status at C1D15 | Number of participants with ECOG PS was reported. ECOG performance status was measured on a 6 point grade scale. 0: Fully active, able to carry on all pre-disease performance without restriction.
| C1D15 |
| Number of Participants With ECOG Performance Status at C1D18 | Number of participants with ECOG PS was reported. ECOG performance status was measured on a 6 point grade scale. 0: Fully active, able to carry on all pre-disease performance without restriction.
| C1D18 |
| Number of Participants With ECOG Performance Status at C1D22 | Number of participants with ECOG PS was reported. ECOG performance status was measured on a 6 point grade scale. 0: Fully active, able to carry on all pre-disease performance without restriction.
| C1D22 |
| Number of Participants With ECOG Performance Status at C1D25 | Number of participants with ECOG PS was reported. ECOG performance status was measured on a 6 point grade scale. 0: Fully active, able to carry on all pre-disease performance without restriction.
| C1D25 |
| Number of Participants With ECOG Performance Status at C2D1 | Number of participants with ECOG PS was reported. ECOG performance status was measured on a 6 point grade scale. 0: Fully active, able to carry on all pre-disease performance without restriction.
| C2D1 |
| Number of Participants With ECOG Performance Status at C2D2 | Number of participants with ECOG PS was reported. ECOG performance status was measured on a 6 point grade scale. 0: Fully active, able to carry on all pre-disease performance without restriction.
| C2D2 |
| Number of Participants With ECOG Performance Status at C2D4 | Number of participants with ECOG PS was reported. ECOG performance status was measured on a 6 point grade scale. 0: Fully active, able to carry on all pre-disease performance without restriction.
| C2D4 |
| Number of Participants With ECOG Performance Status at C2D8 | Number of participants with ECOG PS was reported. ECOG performance status was measured on a 6 point grade scale. 0: Fully active, able to carry on all pre-disease performance without restriction.
| C2D8 |
| Number of Participants With ECOG Performance Status at C2D15 | Number of participants with ECOG PS was reported. ECOG performance status was measured on a 6 point grade scale. 0: Fully active, able to carry on all pre-disease performance without restriction.
| C2D15 |
| Number of Participants With ECOG Performance Status at C2D22 | Number of participants with ECOG PS was reported. ECOG performance status was measured on a 6 point grade scale. 0: Fully active, able to carry on all pre-disease performance without restriction.
| C2D22 |
| Number of Participants With ECOG Performance Status at C3D1 | Number of participants with ECOG PS was reported. ECOG performance status was measured on a 6 point grade scale. 0: Fully active, able to carry on all pre-disease performance without restriction.
| C3D1 |
| Number of Participants With ECOG Performance Status at C3D15 | Number of participants with ECOG PS was reported. ECOG performance status was measured on a 6 point grade scale. 0: Fully active, able to carry on all pre-disease performance without restriction.
| C3D15 |
| Number of Participants With ECOG Performance Status at C4D1 | Number of participants with ECOG PS was reported. ECOG performance status was measured on a 6 point grade scale. 0: Fully active, able to carry on all pre-disease performance without restriction.
| C4D1 |
| Number of Participants With ECOG Performance Status at C4D15 | Number of participants with ECOG PS was reported. ECOG performance status was measured on a 6 point grade scale. 0: Fully active, able to carry on all pre-disease performance without restriction.
| C4D15 |
| Number of Participants With ECOG Performance Status at C5D1 | Number of participants with ECOG PS was reported. ECOG performance status was measured on a 6 point grade scale. 0: Fully active, able to carry on all pre-disease performance without restriction.
| C5D1 |
| Number of Participants With ECOG Performance Status at C5D15 | Number of participants with ECOG PS was reported. ECOG performance status was measured on a 6 point grade scale. 0: Fully active, able to carry on all pre-disease performance without restriction.
| C5D15 |
| Number of Participants With ECOG Performance Status at C6D1 | Number of participants with ECOG PS was reported. ECOG performance status was measured on a 6 point grade scale. 0: Fully active, able to carry on all pre-disease performance without restriction.
| C6D1 |
| Number of Participants With ECOG Performance Status at C6D15 | Number of participants with ECOG PS was reported. ECOG performance status was measured on a 6 point grade scale. 0: Fully active, able to carry on all pre-disease performance without restriction.
| C6D15 |
| Number of Participants With ECOG Performance Status at End of Treatment (EOT) (Dose Escalation Phase) | Number of participants with ECOG PS was reported. ECOG performance status was measured on a 6 point grade scale. 0: Fully active, able to carry on all pre-disease performance without restriction.
EOT was calculated as last dose plus 7 days. | EOT (up to 63 Days) |
| Number of Participants With ECOG Performance Status at EOT (Dose Expansion Phase) | Number of participants with ECOG PS was reported. ECOG performance status was measured on a 6 point grade scale. 0: Fully active, able to carry on all pre-disease performance without restriction.
EOT was calculated as last dose plus 7 days. | EOT (up to 175 days) |
| Number of Participants With ECOG Performance Status at Observation Period (OP) (Week 2) | Number of participants with ECOG PS was reported. ECOG performance status was measured on a 6 point grade scale. 0: Fully active, able to carry on all pre-disease performance without restriction.
OP was the period observed after the last dose. | OP (week 2) |
| Number of Participants With ECOG Performance Status at OP (Week 4) | Number of participants with ECOG PS was reported. ECOG performance status was measured on a 6 point grade scale. 0: Fully active, able to carry on all pre-disease performance without restriction.
OP was the period observed after the last dose. | OP (week 4) |
| Number of Participants With ECOG Performance Status at OP (Week 6) | Number of participants with ECOG PS was reported. ECOG performance status was measured on a 6 point grade scale. 0: Fully active, able to carry on all pre-disease performance without restriction.
OP was the period observed after the last dose. | OP (week 6) |
| Number of Participants With ECOG Performance Status at OP (Week 8) | Number of participants with ECOG PS was reported. ECOG performance status was measured on a 6 point grade scale. 0: Fully active, able to carry on all pre-disease performance without restriction.
OP was the period observed after the last dose. | OP (week 8) |
| Number of Participants With ECOG Performance Status at OP (Week 10) | Number of participants with ECOG PS was reported. ECOG performance status was measured on a 6 point grade scale. 0: Fully active, able to carry on all pre-disease performance without restriction.
OP was the period observed after the last dose. | OP (week 10) |
| Number of Participants With ECOG Performance Status at OP (Week 12) | Number of participants with ECOG PS was reported. ECOG performance status was measured on a 6 point grade scale. 0: Fully active, able to carry on all pre-disease performance without restriction.
OP was the period observed after the last dose. | OP (week 12) |
| From first response up to 43 months |
| Duration of Remission (DR) for Participants With R/R Higher Risk MDS | DR for MDS: included duration of CR and duration of response (i.e., CR + BM CR + PR). CR, BM CR and PR achieved for minimum of 4 weeks; CR: bone marrow: ≤ 5% myeloblasts with normal maturation of all cell Lines, peripheral blood evaluation (hemoglobin (Hb) ≥ 11 g/dL, platelets ≥ 100 × 10^9/L, neutrophils ≥ 1.0 × 10^9/L, 0% blasts in blood) BM CR: bone marrow: ≤ 5% myeloblasts and decrease by ≥ 50% over pretreatment PR: achieved all CR criteria except bone marrow blasts decreased by ≥ 50% over pretreatment but still > 5%, cellularity and morphology not relevant. KM Estimate was used. | From first response up to 43 months |
| Event Free Survival (EFS) | EFS was defined as the time from the date of first dose until the date of documented relapse, treatment failure or death from any cause within 30 days after the last dose of study drug (whichever occurred first earliest of [relapse date, treatment failure date, death date] - first dose date + 1). Relapse was defined as a reappearance of leukemic blasts in the peripheral blood (> 2%) or ≥ 5% blasts in the bone marrow aspirate not attributable to any other cause or reappearance or new appearance of extramedullary leukemia or reappearance of significant numbers of peripheral blasts and an increase in the percentage of blasts in the bone marrow aspirate to > 25% not attributable to any other cause or reappearance or new appearance of extramedullary leukemia. KM Estimate was used. | From first dose up to 43 months |
| Overall Survival (OS) | OS was defined as the time from the date of first dose until the date of death from any cause (death date - first dose date + 1). For a Participant who was not known to have died by the end of study follow-up, OS was censored at the date of last contact (date of last contact - first dose date + 1). KM Estimate was used. | From first dose up to 43 months |
| CR for Participants With R/R AML | Percentage of participants with CR was reported. CR: achieved morphologic leukemia-free state & their bone marrow was regenerating normal hematopoietic cells. If absolute neutrophil count (ANC) ≥ 1 × 10^9/L, platelet count (PC) ≥ 100 × 10^9/L, normal marrow differential < 5% blasts, & were red blood cell (RBC) and platelet transfusion independent (defined as 1 week without RBC transfusion & platelet transfusion prior to disease assessment). There was no evidence of extramedullary leukemia or Auer rods and blast counts in peripheral blood must be ≤ 2%. | From first dose up to 43 months |
| Best Response (CRc + PR) Rates for Participants With R/R AML | Percentage of participants with best response (CRc + PR) was reported. CRc was defined as rate of all complete and incomplete remissions (CR + CR with incomplete platelet recovery [CRp] + CR with incomplete hematological recover [Cri]). CR, CRp and CRi were defined in Outcome measure # 3. PR: achieved bone marrow regenerating normal hematopoietic cells with evidence of peripheral recovery with no (or only a few regenerating) circulating blasts with decrease of at least 50% in the percentage of blasts in bone marrow aspirate with total marrow blasts between 5% and 25%. Value ≤ 5% blasts was considered PR if Auer rods were present. No evidence of extramedullary leukemia. | From first dose up to 43 months |
| CRh for Participants With R/R AML | Percentage of participants with CRh was reported. CRh: achieved marrow blasts < 5%, partial hematologic recovery ANC ≥ 0.5 × 10^9/L and platelets ≥ 50 × 10^9/L, no evidence of extramedullary leukemia and cannot be classified as CR. The blast counts in peripheral blood was ≤ 2%. | From first dose up to 43 months |
| CR for Participants With R/R Higher Risk MDS | Percentage of participants with CR was reported. CR: bone marrow: ≤ 5% myeloblasts with normal maturation of all cell Lines, peripheral blood evaluation (hemoglobin (Hb) ≥ 11 g/dL, platelets ≥ 100 × 10^9/L, neutrophils ≥ 1.0 × 10^9/L, 0% blasts in blood). | From first dose up to 43 months |
| Hematologic Improvement (HI) for Participants With R/R Higher Risk MDS | Percentage of participants with HI was reported. HI: One measurement of the following for at least 8 weeks without cytotoxic therapy:
| From first dose up to 43 months |
| Objective Response (OR) (CR + BM CR + PR + HI) Rates (ORR) for Participants With R/R Higher Risk MDS | Percentage of participants with OR (CR + BM CR + PR + HI) was reported. CR, BM CR & PR achieved for minimum of 4 weeks. CR: BM: ≤ 5% myeloblasts with normal maturation of all cell Lines peripheral blood evaluation (Hb) ≥ 11 g/dL platelets ≥ 100 × 10^9/L, neutrophils ≥ 1.0 × 10^9/L, 0% blasts in blood) BM CR: bone marrow ≤ 5% myeloblasts & decrease by ≥ 50% over pretreatment. PR: achieved all CR criteria except bone marrow blasts decreased ≥ 50% over pretreatment but still > 5% cellularity and morphology not relevant. HI: One measurement of following for at least 8 weeks without cytotoxic therapy.
| From first dose up to 43 months |
| Pembroke Pines |
| Florida |
| 33028 |
| United States |
| NYU Langone Health | New York | New York | 10016 | United States |
| Site JP81005 | Nagoya | Aichi-ken | Japan |
| Site JP81016 | Matsuyama | Ehime | Japan |
| Site JP81009 | Yoshida-gun | Fukui | Japan |
| Site JP81004 | Maebashi | Gunma | Japan |
| Site JP81007 | Kobe | Hyōgo | Japan |
| Site JP81013 | Isehara | Kanagawa | Japan |
| Site JP81017 | Sendai | Miyagi | Japan |
| Site JP81001 | Shinagawa | Tokyo | Japan |
| Site JP81002 | Fukuoka | Japan |
| Site JP81010 | Gifu | Japan |
| Site JP81008 | Okayama | Japan |
| Site JP81011 | Osaka | Japan |
| Site JP81012 | Osaka | Japan |
| FG001 | Dose Escalation (Phase 1): ASP7517 1x10^7 Cells/mL | Participants with R/R AML and R/R higher risk MDS received IV infusion of ASP7517 (HEK293 transfected with encoding target WT-1) at a dose of 1x10^7 cells/mL at 4 to 6 mL/minute infusion rate on day 1 of each cycle for 2 doses (1 cycle= 28 days). |
| FG002 | Dose Escalation (Phase 1): ASP7517 1x10^8 Cells/mL | Participants with R/R AML and R/R higher risk MDS received IV infusion of ASP7517 (HEK293 transfected with encoding target WT-1) at a dose of 1x10^8 cells/mL at 4 to 6 mL/minute infusion rate on day 1 of each cycle for 2 doses (1 cycle= 28 days). |
| FG003 | Dose Expansion (Phase 2: AML): ASP7517 1x10^8 Cells/mL | Participants with R/R AML received IV infusion of ASP7517 (HEK293 transfected with encoding target WT-1) at a dose of 1x10^8 cells/mL at 4 to 6 mL/minute infusion rate on day 1 of each cycle for 6 doses (1 cycle= 28 days). |
| FG004 | Dose Expansion (Phase 2: MDS): ASP7517 1x10^8 Cells/mL | Participants with R/R higher risk MDS received IV infusion of ASP7517 (HEK293 transfected with encoding target WT-1) at a dose of 1x10^8 cells/mL at 4 to 6 mL/minute infusion rate on day 1 of each cycle for 6 doses (1 cycle= 28 days). |
| COMPLETED |
|
| NOT COMPLETED |
|
|
| Dose Expansion Phase (168 Days) |
|
|
The full analysis set (FAS) consisted of all participants who were enrolled and received at least one dose of study drug.
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Dose Escalation (Phase 1): ASP7517 1x10^6 Cells/mL | Participants with R/R AML and R/R higher risk MDS received IV infusion of ASP7517 (HEK293 transfected with encoding target WT-1) at a dose of 1x10^6 cells/mL at 4 to 6 mL/minute infusion rate on day 1 of each cycle for 2 doses (1 cycle= 28 days). |
| BG001 | Dose Escalation (Phase 1): ASP7517 1x10^7 Cells/mL | Participants with R/R AML and R/R higher risk MDS received IV infusion of ASP7517 (HEK293 transfected with encoding target WT-1) at a dose of 1x10^7 cells/mL at 4 to 6 mL/minute infusion rate on day 1 of each cycle for 2 doses (1 cycle= 28 days). |
| BG002 | Dose Escalation (Phase 1): ASP7517 1x10^8 Cells/mL | Participants with R/R AML and R/R higher risk MDS received IV infusion of ASP7517 (HEK293 transfected with encoding target WT-1) at a dose of 1x10^8 cells/mL at 4 to 6 mL/minute infusion rate on day 1 of each cycle for 2 doses (1 cycle= 28 days). |
| BG003 | Dose Expansion (Phase 2: AML): ASP7517 1x10^8 Cells/mL | Participants with R/R AML received IV infusion of ASP7517 (HEK293 transfected with encoding target WT-1) at a dose of 1x10^8 cells/mL at 4 to 6 mL/minute infusion rate on day 1 of each cycle for 6 doses (1 cycle= 28 days). |
| BG004 | Dose Expansion (Phase 2: MDS): ASP7517 1x10^8 Cells/mL | Participants with R/R higher risk MDS received IV infusion of ASP7517 (HEK293 transfected with encoding target WT-1) at a dose of 1x10^8 cells/mL at 4 to 6 mL/minute infusion rate on day 1 of each cycle for 6 doses (1 cycle= 28 days). |
| BG005 | Total | Total of all reporting groups |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean | Standard Deviation | Years |
| |||||||||||||||
| Sex: Female, Male | Count of Participants | Participants |
| ||||||||||||||||
| Ethnicity (NIH/OMB) | Count of Participants | Participants |
| ||||||||||||||||
| Race (NIH/OMB) | Count of Participants | Participants |
| ||||||||||||||||
| ECOG Perfomance Status (PS) | Number of participants with ECOG PS was reported and was measured on 6-point grade scale 0: Fully active, able to carry on all pre-disease performance without restriction
| Number | Participants |
|
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Number of Participants With Dose Limiting Toxicities (DLTs) | DLT was defined as any of the following events that occurred within 28 days starting with the first dose on cycle 1 day 1 (C1D1) and that was considered to be related to study drug. DLT was defined as follows:
| The safety analysis set (SAF) consisted of all participants who were enrolled and received at least 1 dose of study drug. SAF with available data was analyzed | Posted | Number | participants | Day 1 up to 28 days |
|
|
| ||||||||||||||||||||||||||||||||||||||
| Primary | Number of Participants With Treatment Emergent Adverse Events (TEAE) & Serious TEAE | An AE was defined as any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE could therefore be any unfavorable & unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. An AE was considered "serious" if, it resulted in any of the following outcomes: results in death; is life-threatening; results in persistent or significant disability/incapacity or substantial disruption of the ability to conduct normal life functions; results in congenital anomaly, or birth defect; requires inpatient hospitalization; or leads to prolongation of hospitalization; other medically important events. TEAE was defined as an AE observed after starting administration of the study drug. TEAEs included both Serious and non-serious AEs. | SAF | Posted | Number | participants | From first dose up to 43 months |
| ||||||||||||||||||||||||||||||||||||||||
| Primary | Phase 2: Composite Complete Remission (CRc) Rate for Participants With R/R AML | Percentage of participants with CRc was reported. CRc:defined as rate of all complete & incomplete remissions (CR + CR with incomplete platelet recovery [CRp] + CR with incomplete hematological recover [Cri]). CR: achieved morphologic leukemia-free state & their bone marrow was regenerating normal hematopoietic cells. If absolute neutrophil count (ANC) ≥ 1×10^9/L, platelet count (PC) ≥ 100×10^9/L, normal marrow differential < 5% blasts, & were red blood cell (RBC) and platelet transfusion independent (defined as 1 week without RBC transfusion & platelet transfusion prior to disease assessment). There was no evidence of extramedullary leukemia or Auer rods & blast counts in peripheral blood must be ≤ 2%. CRp: must achieve CR except for incomplete platelet recovery (< 100×10^9/L). CRi: must fulfil CR except for incomplete hematological recovery with residual neutropenia (ANC < 1×10^9/L), with or without complete platelet recovery. RBC and platelet transfusion independence not required. | FAS with available data was analyzed | Posted | Number | 90% Confidence Interval | percentage of participants | From first dose up to 43 months |
| |||||||||||||||||||||||||||||||||||||||
| Primary | Phase 2: Complete Remission + Bone Marrow Complete Remission + Partial Remission (CR + BM CR + PR) Rate for Participants With R/R Higher Risk MDS | Percentage of participants with CR+BM CR+ PR was reported. CR, BM CR and PR achieved for minimum of 4 weeks; CR: bone marrow: ≤ 5% myeloblasts with normal maturation of all cell Lines, peripheral blood evaluation (hemoglobin (Hb) ≥ 11 g/dL, platelets ≥ 100 × 10^9/L, neutrophils ≥ 1.0 × 10^9/L, 0% blasts in blood) BM CR: bone marrow: ≤ 5% myeloblasts and decrease by ≥ 50% over pretreatment PR: achieved all CR criteria except bone marrow blasts decreased by ≥ 50% over pretreatment but still > 5%, cellularity and morphology not relevant. | FAS with available data was analyzed | Posted | Number | 90% Confidence Interval | percentage of participants | From first dose up to 43 months |
| |||||||||||||||||||||||||||||||||||||||
| Primary | Number of Participants With ECOG Performance Status at Cycle 1(C1) Day2(D2) | Number of participants with ECOG PS was reported. ECOG performance status was measured on a 6 point grade scale. 0: Fully active, able to carry on all pre-disease performance without restriction.
| SAF with available data was analyzed | Posted | Number | participants | C1D2 |
| ||||||||||||||||||||||||||||||||||||||||
| Primary | Number of Participants With ECOG Performance Status at C1D4 | Number of participants with ECOG PS was reported. ECOG performance status was measured on a 6 point grade scale. 0: Fully active, able to carry on all pre-disease performance without restriction.
| SAF with available data was analyzed | Posted | Number | participants | C1D4 |
| ||||||||||||||||||||||||||||||||||||||||
| Primary | Number of Participants With ECOG Performance Status at C1D8 | Number of participants with ECOG PS was reported. ECOG performance status was measured on a 6 point grade scale. 0: Fully active, able to carry on all pre-disease performance without restriction.
| SAF with available data was analyzed | Posted | Number | participants | C1D8 |
| ||||||||||||||||||||||||||||||||||||||||
| Primary | Number of Participants With ECOG Performance Status at C1D11 | Number of participants with ECOG PS was reported. ECOG performance status was measured on a 6 point grade scale. 0: Fully active, able to carry on all pre-disease performance without restriction.
| SAF with available data was analyzed | Posted | Number | participants | C1D11 |
| ||||||||||||||||||||||||||||||||||||||||
| Primary | Number of Participants With ECOG Performance Status at C1D15 | Number of participants with ECOG PS was reported. ECOG performance status was measured on a 6 point grade scale. 0: Fully active, able to carry on all pre-disease performance without restriction.
| SAF with available data was analyzed | Posted | Number | participants | C1D15 |
| ||||||||||||||||||||||||||||||||||||||||
| Primary | Number of Participants With ECOG Performance Status at C1D18 | Number of participants with ECOG PS was reported. ECOG performance status was measured on a 6 point grade scale. 0: Fully active, able to carry on all pre-disease performance without restriction.
| SAF with available data was analyzed | Posted | Number | participants | C1D18 |
| ||||||||||||||||||||||||||||||||||||||||
| Primary | Number of Participants With ECOG Performance Status at C1D22 | Number of participants with ECOG PS was reported. ECOG performance status was measured on a 6 point grade scale. 0: Fully active, able to carry on all pre-disease performance without restriction.
| SAF with available data was analyzed | Posted | Number | participants | C1D22 |
| ||||||||||||||||||||||||||||||||||||||||
| Primary | Number of Participants With ECOG Performance Status at C1D25 | Number of participants with ECOG PS was reported. ECOG performance status was measured on a 6 point grade scale. 0: Fully active, able to carry on all pre-disease performance without restriction.
| SAF with available data was analyzed | Posted | Number | participants | C1D25 |
| ||||||||||||||||||||||||||||||||||||||||
| Primary | Number of Participants With ECOG Performance Status at C2D1 | Number of participants with ECOG PS was reported. ECOG performance status was measured on a 6 point grade scale. 0: Fully active, able to carry on all pre-disease performance without restriction.
| SAF with available data was analyzed | Posted | Number | participants | C2D1 |
| ||||||||||||||||||||||||||||||||||||||||
| Primary | Number of Participants With ECOG Performance Status at C2D2 | Number of participants with ECOG PS was reported. ECOG performance status was measured on a 6 point grade scale. 0: Fully active, able to carry on all pre-disease performance without restriction.
| SAF with available data was analyzed | Posted | Number | participants | C2D2 |
| ||||||||||||||||||||||||||||||||||||||||
| Primary | Number of Participants With ECOG Performance Status at C2D4 | Number of participants with ECOG PS was reported. ECOG performance status was measured on a 6 point grade scale. 0: Fully active, able to carry on all pre-disease performance without restriction.
| SAF with available data was analyzed | Posted | Number | participants | C2D4 |
| ||||||||||||||||||||||||||||||||||||||||
| Primary | Number of Participants With ECOG Performance Status at C2D8 | Number of participants with ECOG PS was reported. ECOG performance status was measured on a 6 point grade scale. 0: Fully active, able to carry on all pre-disease performance without restriction.
| SAF with available data was analyzed | Posted | Number | participants | C2D8 |
| ||||||||||||||||||||||||||||||||||||||||
| Primary | Number of Participants With ECOG Performance Status at C2D15 | Number of participants with ECOG PS was reported. ECOG performance status was measured on a 6 point grade scale. 0: Fully active, able to carry on all pre-disease performance without restriction.
| SAF with available data was analyzed | Posted | Number | participants | C2D15 |
| ||||||||||||||||||||||||||||||||||||||||
| Primary | Number of Participants With ECOG Performance Status at C2D22 | Number of participants with ECOG PS was reported. ECOG performance status was measured on a 6 point grade scale. 0: Fully active, able to carry on all pre-disease performance without restriction.
| SAF with available data was analyzed | Posted | Number | participants | C2D22 |
| ||||||||||||||||||||||||||||||||||||||||
| Primary | Number of Participants With ECOG Performance Status at C3D1 | Number of participants with ECOG PS was reported. ECOG performance status was measured on a 6 point grade scale. 0: Fully active, able to carry on all pre-disease performance without restriction.
| SAF with available data was analyzed | Posted | Number | participants | C3D1 |
| ||||||||||||||||||||||||||||||||||||||||
| Primary | Number of Participants With ECOG Performance Status at C3D15 | Number of participants with ECOG PS was reported. ECOG performance status was measured on a 6 point grade scale. 0: Fully active, able to carry on all pre-disease performance without restriction.
| SAF with available data was analyzed | Posted | Number | participants | C3D15 |
| ||||||||||||||||||||||||||||||||||||||||
| Primary | Number of Participants With ECOG Performance Status at C4D1 | Number of participants with ECOG PS was reported. ECOG performance status was measured on a 6 point grade scale. 0: Fully active, able to carry on all pre-disease performance without restriction.
| SAF with available data was analyzed | Posted | Number | participants | C4D1 |
| ||||||||||||||||||||||||||||||||||||||||
| Primary | Number of Participants With ECOG Performance Status at C4D15 | Number of participants with ECOG PS was reported. ECOG performance status was measured on a 6 point grade scale. 0: Fully active, able to carry on all pre-disease performance without restriction.
| SAF with available data was analyzed | Posted | Number | participants | C4D15 |
| ||||||||||||||||||||||||||||||||||||||||
| Primary | Number of Participants With ECOG Performance Status at C5D1 | Number of participants with ECOG PS was reported. ECOG performance status was measured on a 6 point grade scale. 0: Fully active, able to carry on all pre-disease performance without restriction.
| SAF with available data was analyzed | Posted | Number | participants | C5D1 |
| ||||||||||||||||||||||||||||||||||||||||
| Primary | Number of Participants With ECOG Performance Status at C5D15 | Number of participants with ECOG PS was reported. ECOG performance status was measured on a 6 point grade scale. 0: Fully active, able to carry on all pre-disease performance without restriction.
| SAF with available data was analyzed | Posted | Number | participants | C5D15 |
| ||||||||||||||||||||||||||||||||||||||||
| Primary | Number of Participants With ECOG Performance Status at C6D1 | Number of participants with ECOG PS was reported. ECOG performance status was measured on a 6 point grade scale. 0: Fully active, able to carry on all pre-disease performance without restriction.
| SAF with available data was analyzed | Posted | Number | participants | C6D1 |
| ||||||||||||||||||||||||||||||||||||||||
| Primary | Number of Participants With ECOG Performance Status at C6D15 | Number of participants with ECOG PS was reported. ECOG performance status was measured on a 6 point grade scale. 0: Fully active, able to carry on all pre-disease performance without restriction.
| SAF with available data was analyzed | Posted | Number | participants | C6D15 |
| ||||||||||||||||||||||||||||||||||||||||
| Primary | Number of Participants With ECOG Performance Status at End of Treatment (EOT) (Dose Escalation Phase) | Number of participants with ECOG PS was reported. ECOG performance status was measured on a 6 point grade scale. 0: Fully active, able to carry on all pre-disease performance without restriction.
EOT was calculated as last dose plus 7 days. | SAF with available data was analyzed | Posted | Number | participants | EOT (up to 63 Days) |
| ||||||||||||||||||||||||||||||||||||||||
| Primary | Number of Participants With ECOG Performance Status at EOT (Dose Expansion Phase) | Number of participants with ECOG PS was reported. ECOG performance status was measured on a 6 point grade scale. 0: Fully active, able to carry on all pre-disease performance without restriction.
EOT was calculated as last dose plus 7 days. | SAF with available data was analyzed | Posted | Number | participants | EOT (up to 175 days) |
| ||||||||||||||||||||||||||||||||||||||||
| Primary | Number of Participants With ECOG Performance Status at Observation Period (OP) (Week 2) | Number of participants with ECOG PS was reported. ECOG performance status was measured on a 6 point grade scale. 0: Fully active, able to carry on all pre-disease performance without restriction.
OP was the period observed after the last dose. | SAF with available data was analyzed | Posted | Number | participants | OP (week 2) |
| ||||||||||||||||||||||||||||||||||||||||
| Primary | Number of Participants With ECOG Performance Status at OP (Week 4) | Number of participants with ECOG PS was reported. ECOG performance status was measured on a 6 point grade scale. 0: Fully active, able to carry on all pre-disease performance without restriction.
OP was the period observed after the last dose. | SAF with available data was analyzed | Posted | Number | participants | OP (week 4) |
| ||||||||||||||||||||||||||||||||||||||||
| Primary | Number of Participants With ECOG Performance Status at OP (Week 6) | Number of participants with ECOG PS was reported. ECOG performance status was measured on a 6 point grade scale. 0: Fully active, able to carry on all pre-disease performance without restriction.
OP was the period observed after the last dose. | SAF with available data was analyzed | Posted | Number | participants | OP (week 6) |
| ||||||||||||||||||||||||||||||||||||||||
| Primary | Number of Participants With ECOG Performance Status at OP (Week 8) | Number of participants with ECOG PS was reported. ECOG performance status was measured on a 6 point grade scale. 0: Fully active, able to carry on all pre-disease performance without restriction.
OP was the period observed after the last dose. | SAF with available data was analyzed | Posted | Number | participants | OP (week 8) |
| ||||||||||||||||||||||||||||||||||||||||
| Primary | Number of Participants With ECOG Performance Status at OP (Week 10) | Number of participants with ECOG PS was reported. ECOG performance status was measured on a 6 point grade scale. 0: Fully active, able to carry on all pre-disease performance without restriction.
OP was the period observed after the last dose. | SAF with available data was analyzed | Posted | Number | participants | OP (week 10) |
| ||||||||||||||||||||||||||||||||||||||||
| Primary | Number of Participants With ECOG Performance Status at OP (Week 12) | Number of participants with ECOG PS was reported. ECOG performance status was measured on a 6 point grade scale. 0: Fully active, able to carry on all pre-disease performance without restriction.
OP was the period observed after the last dose. | SAF with available data was analyzed | Posted | Number | participants | OP (week 12) |
| ||||||||||||||||||||||||||||||||||||||||
| Secondary | Duration of Remission (DR) for Participants With R/R AML | DR for AML: included duration of CRc, duration of CR/complete remission with partial hematologic recovery (CRh), duration of CRh, duration of CR, and duration of response (i.e., CRc + PR). CRh: achieved marrow blasts < 5%, partial hematologic recovery ANC ≥ 0.5 × 10^9/L and platelets ≥ 50 × 10^9/L, no evidence of extramedullary leukemia and cannot be classified as CR. The blast counts in peripheral blood was ≤ 2%. PR for AML; achieved bone marrow regenerating normal hematopoietic cells with evidence of peripheral recovery with no (or only a few regenerating) circulating blasts with decrease of at least 50% in the percentage of blasts in bone marrow aspirate with total marrow blasts between 5% and 25%. Value ≤ 5% blasts was considered PR if Auer rods were present. No evidence of extramedullary leukemia. CR, CRc were defined in outcome measure #3. Kaplan Meier (KM) Estimate was used. | Response Analysis Set (RAS) included FAS participants and had at least 1 post baseline primary efficacy measurement. As per change in the planned analysis, the dose level utilized during the expansion phase was the RP2D, which was carefully selected from the dose escalation phase and a pooled population was used to estimate time-to-event efficacy endpoints for a comprehensive overview of the treatment's effectiveness. | Posted | Median | 90% Confidence Interval | days | From first response up to 43 months |
| |||||||||||||||||||||||||||||||||||||||
| Secondary | Duration of Remission (DR) for Participants With R/R Higher Risk MDS | DR for MDS: included duration of CR and duration of response (i.e., CR + BM CR + PR). CR, BM CR and PR achieved for minimum of 4 weeks; CR: bone marrow: ≤ 5% myeloblasts with normal maturation of all cell Lines, peripheral blood evaluation (hemoglobin (Hb) ≥ 11 g/dL, platelets ≥ 100 × 10^9/L, neutrophils ≥ 1.0 × 10^9/L, 0% blasts in blood) BM CR: bone marrow: ≤ 5% myeloblasts and decrease by ≥ 50% over pretreatment PR: achieved all CR criteria except bone marrow blasts decreased by ≥ 50% over pretreatment but still > 5%, cellularity and morphology not relevant. KM Estimate was used. | RAS As per change in the planned analysis, the dose level utilized during the expansion phase was the RP2D, which was carefully selected from the dose escalation phase and a pooled population was used to estimate time-to-event efficacy endpoints for a comprehensive overview of the treatment's effectiveness. | Posted | Median | 90% Confidence Interval | days | From first response up to 43 months |
| |||||||||||||||||||||||||||||||||||||||
| Secondary | Event Free Survival (EFS) | EFS was defined as the time from the date of first dose until the date of documented relapse, treatment failure or death from any cause within 30 days after the last dose of study drug (whichever occurred first earliest of [relapse date, treatment failure date, death date] - first dose date + 1). Relapse was defined as a reappearance of leukemic blasts in the peripheral blood (> 2%) or ≥ 5% blasts in the bone marrow aspirate not attributable to any other cause or reappearance or new appearance of extramedullary leukemia or reappearance of significant numbers of peripheral blasts and an increase in the percentage of blasts in the bone marrow aspirate to > 25% not attributable to any other cause or reappearance or new appearance of extramedullary leukemia. KM Estimate was used. | FAS As per change in the planned analysis, the dose level utilized during the expansion phase was the RP2D, which was carefully selected from the dose escalation phase and a pooled population was used to estimate time-to-event efficacy endpoints for a comprehensive overview of the treatment's effectiveness. | Posted | Median | 90% Confidence Interval | days | From first dose up to 43 months |
| |||||||||||||||||||||||||||||||||||||||
| Secondary | Overall Survival (OS) | OS was defined as the time from the date of first dose until the date of death from any cause (death date - first dose date + 1). For a Participant who was not known to have died by the end of study follow-up, OS was censored at the date of last contact (date of last contact - first dose date + 1). KM Estimate was used. | FAS As per change in the planned analysis, the dose level utilized during the expansion phase was the RP2D, which was carefully selected from the dose escalation phase and a pooled population was used to estimate time-to-event efficacy endpoints for a comprehensive overview of the treatment's effectiveness. | Posted | Median | 90% Confidence Interval | days | From first dose up to 43 months |
| |||||||||||||||||||||||||||||||||||||||
| Secondary | CR for Participants With R/R AML | Percentage of participants with CR was reported. CR: achieved morphologic leukemia-free state & their bone marrow was regenerating normal hematopoietic cells. If absolute neutrophil count (ANC) ≥ 1 × 10^9/L, platelet count (PC) ≥ 100 × 10^9/L, normal marrow differential < 5% blasts, & were red blood cell (RBC) and platelet transfusion independent (defined as 1 week without RBC transfusion & platelet transfusion prior to disease assessment). There was no evidence of extramedullary leukemia or Auer rods and blast counts in peripheral blood must be ≤ 2%. | FAS with available data was analyzed. | Posted | Number | percentage of participants | From first dose up to 43 months |
| ||||||||||||||||||||||||||||||||||||||||
| Secondary | Best Response (CRc + PR) Rates for Participants With R/R AML | Percentage of participants with best response (CRc + PR) was reported. CRc was defined as rate of all complete and incomplete remissions (CR + CR with incomplete platelet recovery [CRp] + CR with incomplete hematological recover [Cri]). CR, CRp and CRi were defined in Outcome measure # 3. PR: achieved bone marrow regenerating normal hematopoietic cells with evidence of peripheral recovery with no (or only a few regenerating) circulating blasts with decrease of at least 50% in the percentage of blasts in bone marrow aspirate with total marrow blasts between 5% and 25%. Value ≤ 5% blasts was considered PR if Auer rods were present. No evidence of extramedullary leukemia. | FAS with available data was analyzed | Posted | Number | 90% Confidence Interval | percentage of participants | From first dose up to 43 months |
| |||||||||||||||||||||||||||||||||||||||
| Secondary | CRh for Participants With R/R AML | Percentage of participants with CRh was reported. CRh: achieved marrow blasts < 5%, partial hematologic recovery ANC ≥ 0.5 × 10^9/L and platelets ≥ 50 × 10^9/L, no evidence of extramedullary leukemia and cannot be classified as CR. The blast counts in peripheral blood was ≤ 2%. | FAS with available data was analyzed | Posted | Number | percentage of participants | From first dose up to 43 months |
| ||||||||||||||||||||||||||||||||||||||||
| Secondary | CR for Participants With R/R Higher Risk MDS | Percentage of participants with CR was reported. CR: bone marrow: ≤ 5% myeloblasts with normal maturation of all cell Lines, peripheral blood evaluation (hemoglobin (Hb) ≥ 11 g/dL, platelets ≥ 100 × 10^9/L, neutrophils ≥ 1.0 × 10^9/L, 0% blasts in blood). | FAS with available data was analyzed. | Posted | Number | percentage of participants | From first dose up to 43 months |
| ||||||||||||||||||||||||||||||||||||||||
| Secondary | Hematologic Improvement (HI) for Participants With R/R Higher Risk MDS | Percentage of participants with HI was reported. HI: One measurement of the following for at least 8 weeks without cytotoxic therapy:
| FAS with available data was analyzed. | Posted | Number | percentage of participants | From first dose up to 43 months |
| ||||||||||||||||||||||||||||||||||||||||
| Secondary | Objective Response (OR) (CR + BM CR + PR + HI) Rates (ORR) for Participants With R/R Higher Risk MDS | Percentage of participants with OR (CR + BM CR + PR + HI) was reported. CR, BM CR & PR achieved for minimum of 4 weeks. CR: BM: ≤ 5% myeloblasts with normal maturation of all cell Lines peripheral blood evaluation (Hb) ≥ 11 g/dL platelets ≥ 100 × 10^9/L, neutrophils ≥ 1.0 × 10^9/L, 0% blasts in blood) BM CR: bone marrow ≤ 5% myeloblasts & decrease by ≥ 50% over pretreatment. PR: achieved all CR criteria except bone marrow blasts decreased ≥ 50% over pretreatment but still > 5% cellularity and morphology not relevant. HI: One measurement of following for at least 8 weeks without cytotoxic therapy.
| FAS with available data was analyzed. | Posted | Number | 90% Confidence Interval | percentage of participants | From first dose up to 43 months |
|
From first dose up to 43 months
SAF
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Dose Escalation (Phase 1): ASP7517 1x10^6 Cells/mL | Participants with R/R AML and R/R higher risk MDS received IV infusion of ASP7517 (HEK293 transfected with encoding target WT-1) at a dose of 1x10^6 cells/mL at 4 to 6 mL/minute infusion rate on day 1 of each cycle for 2 doses (1 cycle= 28 days). | 6 | 6 | 1 | 6 | 5 | 6 |
| EG001 | Dose Escalation (Phase 1): ASP7517 1x10^7 Cells/mL | Participants with R/R AML and R/R higher risk MDS received IV infusion of ASP7517 (HEK293 transfected with encoding target WT-1) at a dose of 1x10^7 cells/mL at 4 to 6 mL/minute infusion rate on day 1 of each cycle for 2 doses (1 cycle= 28 days). | 5 | 5 | 4 | 5 | 4 | 5 |
| EG002 | Dose Escalation (Phase 1): ASP7517 1x10^8 Cells/mL | Participants with R/R AML and R/R higher risk MDS received IV infusion of ASP7517 (HEK293 transfected with encoding target WT-1) at a dose of 1x10^8 cells/mL at 4 to 6 mL/minute infusion rate on day 1 of each cycle for 2 doses (1 cycle= 28 days). | 7 | 8 | 2 | 8 | 6 | 8 |
| EG003 | Dose Expansion (Phase 2: AML): ASP7517 1x10^8 Cells/mL | Participants with R/R AML received IV infusion of ASP7517 (HEK293 transfected with encoding target WT-1) at a dose of 1x10^8 cells/mL at 4 to 6 mL/minute infusion rate on day 1 of each cycle for 6 doses (1 cycle= 28 days). | 9 | 12 | 8 | 12 | 10 | 12 |
| EG004 | Dose Expansion (Phase 2: MDS): ASP7517 1x10^8 Cells/mL | Participants with R/R higher risk MDS received IV infusion of ASP7517 (HEK293 transfected with encoding target WT-1) at a dose of 1x10^8 cells/mL at 4 to 6 mL/minute infusion rate on day 1 of each cycle for 6 doses (1 cycle= 28 days). | 5 | 12 | 5 | 12 | 10 | 12 |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Febrile neutropenia | Blood and lymphatic system disorders | MedDRA v26.0 | Systematic Assessment |
| |
| Atrial fibrillation | Cardiac disorders | MedDRA v26.0 | Systematic Assessment |
| |
| Cardiac failure | Cardiac disorders | MedDRA v26.0 | Systematic Assessment |
| |
| Pyrexia | General disorders | MedDRA v26.0 | Systematic Assessment |
| |
| Cellulitis | Infections and infestations | MedDRA v26.0 | Systematic Assessment |
| |
| Device related infection | Infections and infestations | MedDRA v26.0 | Systematic Assessment |
| |
| Pneumonia | Infections and infestations | MedDRA v26.0 | Systematic Assessment |
| |
| Pneumonia fungal | Infections and infestations | MedDRA v26.0 | Systematic Assessment |
| |
| Sepsis | Infections and infestations | MedDRA v26.0 | Systematic Assessment |
| |
| Septic shock | Infections and infestations | MedDRA v26.0 | Systematic Assessment |
| |
| Subdural haematoma | Injury, poisoning and procedural complications | MedDRA v26.0 | Systematic Assessment |
| |
| Arthritis | Musculoskeletal and connective tissue disorders | MedDRA v26.0 | Systematic Assessment |
| |
| Acute myeloid leukaemia | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA v26.0 | Systematic Assessment |
| |
| Tumour associated fever | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA v26.0 | Systematic Assessment |
| |
| Device physical property issue | Product Issues | MedDRA v26.0 | Systematic Assessment |
| |
| Delirium | Psychiatric disorders | MedDRA v26.0 | Systematic Assessment |
| |
| Dyspnoea | Respiratory, thoracic and mediastinal disorders | MedDRA v26.0 | Systematic Assessment |
|
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Anaemia | Blood and lymphatic system disorders | MedDRA v26.0 | Systematic Assessment |
| |
| Febrile neutropenia | Blood and lymphatic system disorders | MedDRA v26.0 | Systematic Assessment |
| |
| Neutropenia | Blood and lymphatic system disorders | MedDRA v26.0 | Systematic Assessment |
| |
| Splenomegaly | Blood and lymphatic system disorders | MedDRA v26.0 | Systematic Assessment |
| |
| Thrombocytopenia | Blood and lymphatic system disorders | MedDRA v26.0 | Systematic Assessment |
| |
| Atrial fibrillation | Cardiac disorders | MedDRA v26.0 | Systematic Assessment |
| |
| Cardiac failure | Cardiac disorders | MedDRA v26.0 | Systematic Assessment |
| |
| Abdominal discomfort | Gastrointestinal disorders | MedDRA v26.0 | Systematic Assessment |
| |
| Cheilitis | Gastrointestinal disorders | MedDRA v26.0 | Systematic Assessment |
| |
| Constipation | Gastrointestinal disorders | MedDRA v26.0 | Systematic Assessment |
| |
| Diarrhoea | Gastrointestinal disorders | MedDRA v26.0 | Systematic Assessment |
| |
| Haemorrhoids | Gastrointestinal disorders | MedDRA v26.0 | Systematic Assessment |
| |
| Mouth haemorrhage | Gastrointestinal disorders | MedDRA v26.0 | Systematic Assessment |
| |
| Nausea | Gastrointestinal disorders | MedDRA v26.0 | Systematic Assessment |
| |
| Oral pain | Gastrointestinal disorders | MedDRA v26.0 | Systematic Assessment |
| |
| Proctitis | Gastrointestinal disorders | MedDRA v26.0 | Systematic Assessment |
| |
| Stomatitis | Gastrointestinal disorders | MedDRA v26.0 | Systematic Assessment |
| |
| Vomiting | Gastrointestinal disorders | MedDRA v26.0 | Systematic Assessment |
| |
| Catheter site pain | General disorders | MedDRA v26.0 | Systematic Assessment |
| |
| Chest discomfort | General disorders | MedDRA v26.0 | Systematic Assessment |
| |
| Chills | General disorders | MedDRA v26.0 | Systematic Assessment |
| |
| Fatigue | General disorders | MedDRA v26.0 | Systematic Assessment |
| |
| Malaise | General disorders | MedDRA v26.0 | Systematic Assessment |
| |
| Non-cardiac chest pain | General disorders | MedDRA v26.0 | Systematic Assessment |
| |
| Oedema | General disorders | MedDRA v26.0 | Systematic Assessment |
| |
| Oedema peripheral | General disorders | MedDRA v26.0 | Systematic Assessment |
| |
| Pyrexia | General disorders | MedDRA v26.0 | Systematic Assessment |
| |
| Liver disorder | Hepatobiliary disorders | MedDRA v26.0 | Systematic Assessment |
| |
| COVID-19 | Infections and infestations | MedDRA v26.0 | Systematic Assessment |
| |
| Diverticulitis | Infections and infestations | MedDRA v26.0 | Systematic Assessment |
| |
| Enterocolitis bacterial | Infections and infestations | MedDRA v26.0 | Systematic Assessment |
| |
| Nasopharyngitis | Infections and infestations | MedDRA v26.0 | Systematic Assessment |
| |
| Pharyngitis | Infections and infestations | MedDRA v26.0 | Systematic Assessment |
| |
| Pneumonia | Infections and infestations | MedDRA v26.0 | Systematic Assessment |
| |
| Sepsis | Infections and infestations | MedDRA v26.0 | Systematic Assessment |
| |
| Allergic transfusion reaction | Injury, poisoning and procedural complications | MedDRA v26.0 | Systematic Assessment |
| |
| Extradural haematoma | Injury, poisoning and procedural complications | MedDRA v26.0 | Systematic Assessment |
| |
| Fall | Injury, poisoning and procedural complications | MedDRA v26.0 | Systematic Assessment |
| |
| Skin abrasion | Injury, poisoning and procedural complications | MedDRA v26.0 | Systematic Assessment |
| |
| Alanine aminotransferase increased | Investigations | MedDRA v26.0 | Systematic Assessment |
| |
| Aspartate aminotransferase increased | Investigations | MedDRA v26.0 | Systematic Assessment |
| |
| Blood alkaline phosphatase increased | Investigations | MedDRA v26.0 | Systematic Assessment |
| |
| Blood bilirubin increased | Investigations | MedDRA v26.0 | Systematic Assessment |
| |
| Blood creatinine increased | Investigations | MedDRA v26.0 | Systematic Assessment |
| |
| Blood lactate dehydrogenase increased | Investigations | MedDRA v26.0 | Systematic Assessment |
| |
| Fibrin D dimer increased | Investigations | MedDRA v26.0 | Systematic Assessment |
| |
| Lymphocyte count decreased | Investigations | MedDRA v26.0 | Systematic Assessment |
| |
| Neutrophil count decreased | Investigations | MedDRA v26.0 | Systematic Assessment |
| |
| White blood cell count decreased | Investigations | MedDRA v26.0 | Systematic Assessment |
| |
| Decreased appetite | Metabolism and nutrition disorders | MedDRA v26.0 | Systematic Assessment |
| |
| Hypoalbuminaemia | Metabolism and nutrition disorders | MedDRA v26.0 | Systematic Assessment |
| |
| Hypokalaemia | Metabolism and nutrition disorders | MedDRA v26.0 | Systematic Assessment |
| |
| Arthralgia | Musculoskeletal and connective tissue disorders | MedDRA v26.0 | Systematic Assessment |
| |
| Arthritis | Musculoskeletal and connective tissue disorders | MedDRA v26.0 | Systematic Assessment |
| |
| Muscular weakness | Musculoskeletal and connective tissue disorders | MedDRA v26.0 | Systematic Assessment |
| |
| Musculoskeletal stiffness | Musculoskeletal and connective tissue disorders | MedDRA v26.0 | Systematic Assessment |
| |
| Pain in extremity | Musculoskeletal and connective tissue disorders | MedDRA v26.0 | Systematic Assessment |
| |
| Tumour associated fever | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA v26.0 | Systematic Assessment |
| |
| Dizziness | Nervous system disorders | MedDRA v26.0 | Systematic Assessment |
| |
| Headache | Nervous system disorders | MedDRA v26.0 | Systematic Assessment |
| |
| Occipital neuralgia | Nervous system disorders | MedDRA v26.0 | Systematic Assessment |
| |
| Paraesthesia | Nervous system disorders | MedDRA v26.0 | Systematic Assessment |
| |
| Insomnia | Psychiatric disorders | MedDRA v26.0 | Systematic Assessment |
| |
| Haematuria | Renal and urinary disorders | MedDRA v26.0 | Systematic Assessment |
| |
| Benign prostatic hyperplasia | Reproductive system and breast disorders | MedDRA v26.0 | Systematic Assessment |
| |
| Cough | Respiratory, thoracic and mediastinal disorders | MedDRA v26.0 | Systematic Assessment |
| |
| Dyspnoea | Respiratory, thoracic and mediastinal disorders | MedDRA v26.0 | Systematic Assessment |
| |
| Epistaxis | Respiratory, thoracic and mediastinal disorders | MedDRA v26.0 | Systematic Assessment |
| |
| Hiccups | Respiratory, thoracic and mediastinal disorders | MedDRA v26.0 | Systematic Assessment |
| |
| Oropharyngeal pain | Respiratory, thoracic and mediastinal disorders | MedDRA v26.0 | Systematic Assessment |
| |
| Pleural effusion | Respiratory, thoracic and mediastinal disorders | MedDRA v26.0 | Systematic Assessment |
| |
| Pneumonitis | Respiratory, thoracic and mediastinal disorders | MedDRA v26.0 | Systematic Assessment |
| |
| Productive cough | Respiratory, thoracic and mediastinal disorders | MedDRA v26.0 | Systematic Assessment |
| |
| Drug eruption | Skin and subcutaneous tissue disorders | MedDRA v26.0 | Systematic Assessment |
| |
| Erythema | Skin and subcutaneous tissue disorders | MedDRA v26.0 | Systematic Assessment |
| |
| Pruritus | Skin and subcutaneous tissue disorders | MedDRA v26.0 | Systematic Assessment |
| |
| Purpura | Skin and subcutaneous tissue disorders | MedDRA v26.0 | Systematic Assessment |
| |
| Rash | Skin and subcutaneous tissue disorders | MedDRA v26.0 | Systematic Assessment |
| |
| Rash macular | Skin and subcutaneous tissue disorders | MedDRA v26.0 | Systematic Assessment |
| |
| Urticaria | Skin and subcutaneous tissue disorders | MedDRA v26.0 | Systematic Assessment |
| |
| Hypotension | Vascular disorders | MedDRA v26.0 | Systematic Assessment |
| |
| Vasculitis | Vascular disorders | MedDRA v26.0 | Systematic Assessment |
|
Institute and/or Principal Investigator may publish trial data generated at their specific study site after Sponsor publication of the multi-center data. Sponsor must receive a site's manuscript prior to publication for review and comment as specified in the Investigator Agreement
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Clinical Trial Disclosure | Astellas Pharma Global Development Inc | 8008887704 | astellas.resultsdisclosure@astellas.com |
| Prot_000.pdf |
| SAP | No | Yes | No | Statistical Analysis Plan | Jun 27, 2023 | Apr 12, 2024 | SAP_001.pdf |
Not provided
| ID | Term |
|---|---|
| D015470 | Leukemia, Myeloid, Acute |
| D009190 | Myelodysplastic Syndromes |
| ID | Term |
|---|---|
| D007951 | Leukemia, Myeloid |
| D007938 | Leukemia |
| D009370 | Neoplasms by Histologic Type |
| D009369 | Neoplasms |
| D006402 | Hematologic Diseases |
| D006425 | Hemic and Lymphatic Diseases |
| D001855 | Bone Marrow Diseases |
Not provided
Not provided
| Withdrawal by Subject |
|
| Physician Decision |
|
| Progressive Disease |
|
| Lack of Efficacy |
|
| Death |
|
| Male |
|
| Not Hispanic or Latino |
|
| Unknown or Not Reported |
|
| Asian |
|
| Native Hawaiian or Other Pacific Islander |
|
| Black or African American |
|
| White |
|
| More than one race |
|
| Unknown or Not Reported |
|
| Grade 1 |
|
| Grade 2 |
|
| Grade 3 |
|
| Grade 4 |
|
| Grade 5 |
|
Participants with R/R AML and R/R higher risk MDS received IV infusion of ASP7517 (HEK293 transfected with encoding target WT-1) at a dose of 1x10^7 cells/mL at 4 to 6 mL/minute infusion rate on day 1 of each cycle for 2 doses (1 cycle= 28 days).
| OG002 | Dose Escalation (Phase 1): ASP7517 1x10^8 Cells/mL | Participants with R/R AML and R/R higher risk MDS received IV infusion of ASP7517 (HEK293 transfected with encoding target WT-1) at a dose of 1x10^8 cells/mL at 4 to 6 mL/minute infusion rate on day 1 of each cycle for 2 doses (1 cycle= 28 days). |
| OG003 | Dose Expansion (Phase 2: AML): ASP7517 1x10^8 Cells/mL | Participants with R/R AML received IV infusion of ASP7517 (HEK293 transfected with encoding target WT-1) at a dose of 1x10^8 cells/mL at 4 to 6 mL/minute infusion rate on day 1 of each cycle for 6 doses (1 cycle= 28 days). |
| OG004 | Dose Expansion (Phase 2: MDS): ASP7517 1x10^8 Cells/mL | Participants with R/R higher risk MDS received IV infusion of ASP7517 (HEK293 transfected with encoding target WT-1) at a dose of 1x10^8 cells/mL at 4 to 6 mL/minute infusion rate on day 1 of each cycle for 6 doses (1 cycle= 28 days). |
|
|
Participants with R/R AML received IV infusion of ASP7517 (HEK293 transfected with encoding target WT-1) at a dose of 1x10^7 cells/mL at 4 to 6 mL/minute infusion rate on day 1 of each cycle for 2 doses (1 cycle= 28 days). |
| OG002 | Dose Escalation (Phase 1) (AML): ASP7517 1x10^8 Cells/mL | Participants with R/R AML received IV infusion of ASP7517 (HEK293 transfected with encoding target WT-1) at a dose of 1x10^8 cells/mL at 4 to 6 mL/minute infusion rate on day 1 of each cycle for 2 doses (1 cycle= 28 days). |
| OG003 | Dose Expansion (Phase 2: AML): ASP7517 1x10^8 Cells/mL | Participants with R/R AML received IV infusion of ASP7517 (HEK293 transfected with encoding target WT-1) at a dose of 1x10^8 cells/mL at 4 to 6 mL/minute infusion rate on day 1 of each cycle for 6 doses (1 cycle= 28 days). |
|
|
| OG002 | Dose Escalation (Phase 1) (MDS): ASP7517 1x10^8 Cells/mL | Participants with R/R higher risk MDS received IV infusion of ASP7517 (HEK293 transfected with encoding target WT-1) at a dose of 1x10^8 cells/mL at 4 to 6 mL/minute infusion rate on day 1 of each cycle for 2 doses (1 cycle= 28 days). |
| OG003 | Dose Expansion (Phase 2: MDS): ASP7517 1x10^8 Cells/mL | Participants with R/R higher risk MDS received IV infusion of ASP7517 (HEK293 transfected with encoding target WT-1) at a dose of 1x10^8 cells/mL at 4 to 6 mL/minute infusion rate on day 1 of each cycle for 6 doses (1 cycle= 28 days). |
|
|
| OG002 | Dose Escalation (Phase 1): ASP7517 1x10^8 Cells/mL | Participants with R/R AML and R/R higher risk MDS received IV infusion of ASP7517 (HEK293 transfected with encoding target WT-1) at a dose of 1x10^8 cells/mL at 4 to 6 mL/minute infusion rate on day 1 of each cycle for 2 doses (1 cycle= 28 days). |
| OG003 | Dose Expansion (Phase 2: AML): ASP7517 1x10^8 Cells/mL | Participants with R/R AML received IV infusion of ASP7517 (HEK293 transfected with encoding target WT-1) at a dose of 1x10^8 cells/mL at 4 to 6 mL/minute infusion rate on day 1 of each cycle for 6 doses (1 cycle= 28 days). |
| OG004 | Dose Expansion (Phase 2: MDS): ASP7517 1x10^8 Cells/mL | Participants with R/R higher risk MDS received IV infusion of ASP7517 (HEK293 transfected with encoding target WT-1) at a dose of 1x10^8 cells/mL at 4 to 6 mL/minute infusion rate on day 1 of each cycle for 6 doses (1 cycle= 28 days). |
|
|
| OG002 | Dose Escalation (Phase 1): ASP7517 1x10^8 Cells/mL | Participants with R/R AML and R/R higher risk MDS received IV infusion of ASP7517 (HEK293 transfected with encoding target WT-1) at a dose of 1x10^8 cells/mL at 4 to 6 mL/minute infusion rate on day 1 of each cycle for 2 doses (1 cycle= 28 days). |
| OG003 | Dose Expansion (Phase 2: AML): ASP7517 1x10^8 Cells/mL | Participants with R/R AML received IV infusion of ASP7517 (HEK293 transfected with encoding target WT-1) at a dose of 1x10^8 cells/mL at 4 to 6 mL/minute infusion rate on day 1 of each cycle for 6 doses (1 cycle= 28 days). |
| OG004 | Dose Expansion (Phase 2: MDS): ASP7517 1x10^8 Cells/mL | Participants with R/R higher risk MDS received IV infusion of ASP7517 (HEK293 transfected with encoding target WT-1) at a dose of 1x10^8 cells/mL at 4 to 6 mL/minute infusion rate on day 1 of each cycle for 6 doses (1 cycle= 28 days). |
|
|
| OG002 | Dose Escalation (Phase 1): ASP7517 1x10^8 Cells/mL | Participants with R/R AML and R/R higher risk MDS received IV infusion of ASP7517 (HEK293 transfected with encoding target WT-1) at a dose of 1x10^8 cells/mL at 4 to 6 mL/minute infusion rate on day 1 of each cycle for 2 doses (1 cycle= 28 days). |
| OG003 | Dose Expansion (Phase 2: AML): ASP7517 1x10^8 Cells/mL | Participants with R/R AML received IV infusion of ASP7517 (HEK293 transfected with encoding target WT-1) at a dose of 1x10^8 cells/mL at 4 to 6 mL/minute infusion rate on day 1 of each cycle for 6 doses (1 cycle= 28 days). |
| OG004 | Dose Expansion (Phase 2: MDS): ASP7517 1x10^8 Cells/mL | Participants with R/R higher risk MDS received IV infusion of ASP7517 (HEK293 transfected with encoding target WT-1) at a dose of 1x10^8 cells/mL at 4 to 6 mL/minute infusion rate on day 1 of each cycle for 6 doses (1 cycle= 28 days). |
|
|
| OG002 | Dose Escalation (Phase 1): ASP7517 1x10^8 Cells/mL | Participants with R/R AML and R/R higher risk MDS received IV infusion of ASP7517 (HEK293 transfected with encoding target WT-1) at a dose of 1x10^8 cells/mL at 4 to 6 mL/minute infusion rate on day 1 of each cycle for 2 doses (1 cycle= 28 days). |
| OG003 | Dose Expansion (Phase 2: AML): ASP7517 1x10^8 Cells/mL | Participants with R/R AML received IV infusion of ASP7517 (HEK293 transfected with encoding target WT-1) at a dose of 1x10^8 cells/mL at 4 to 6 mL/minute infusion rate on day 1 of each cycle for 6 doses (1 cycle= 28 days). |
| OG004 | Dose Expansion (Phase 2: MDS): ASP7517 1x10^8 Cells/mL | Participants with R/R higher risk MDS received IV infusion of ASP7517 (HEK293 transfected with encoding target WT-1) at a dose of 1x10^8 cells/mL at 4 to 6 mL/minute infusion rate on day 1 of each cycle for 6 doses (1 cycle= 28 days). |
|
|
| OG002 | Dose Escalation (Phase 1): ASP7517 1x10^8 Cells/mL | Participants with R/R AML and R/R higher risk MDS received IV infusion of ASP7517 (HEK293 transfected with encoding target WT-1) at a dose of 1x10^8 cells/mL at 4 to 6 mL/minute infusion rate on day 1 of each cycle for 2 doses (1 cycle= 28 days). |
| OG003 | Dose Expansion (Phase 2: AML): ASP7517 1x10^8 Cells/mL | Participants with R/R AML received IV infusion of ASP7517 (HEK293 transfected with encoding target WT-1) at a dose of 1x10^8 cells/mL at 4 to 6 mL/minute infusion rate on day 1 of each cycle for 6 doses (1 cycle= 28 days). |
| OG004 | Dose Expansion (Phase 2: MDS): ASP7517 1x10^8 Cells/mL | Participants with R/R higher risk MDS received IV infusion of ASP7517 (HEK293 transfected with encoding target WT-1) at a dose of 1x10^8 cells/mL at 4 to 6 mL/minute infusion rate on day 1 of each cycle for 6 doses (1 cycle= 28 days). |
|
|
| OG002 | Dose Escalation (Phase 1): ASP7517 1x10^8 Cells/mL | Participants with R/R AML and R/R higher risk MDS received IV infusion of ASP7517 (HEK293 transfected with encoding target WT-1) at a dose of 1x10^8 cells/mL at 4 to 6 mL/minute infusion rate on day 1 of each cycle for 2 doses (1 cycle= 28 days). |
| OG003 | Dose Expansion (Phase 2: AML): ASP7517 1x10^8 Cells/mL | Participants with R/R AML received IV infusion of ASP7517 (HEK293 transfected with encoding target WT-1) at a dose of 1x10^8 cells/mL at 4 to 6 mL/minute infusion rate on day 1 of each cycle for 6 doses (1 cycle= 28 days). |
| OG004 | Dose Expansion (Phase 2: MDS): ASP7517 1x10^8 Cells/mL | Participants with R/R higher risk MDS received IV infusion of ASP7517 (HEK293 transfected with encoding target WT-1) at a dose of 1x10^8 cells/mL at 4 to 6 mL/minute infusion rate on day 1 of each cycle for 6 doses (1 cycle= 28 days). |
|
|
| OG002 | Dose Escalation (Phase 1): ASP7517 1x10^8 Cells/mL | Participants with R/R AML and R/R higher risk MDS received IV infusion of ASP7517 (HEK293 transfected with encoding target WT-1) at a dose of 1x10^8 cells/mL at 4 to 6 mL/minute infusion rate on day 1 of each cycle for 2 doses (1 cycle= 28 days). |
| OG003 | Dose Expansion (Phase 2: AML): ASP7517 1x10^8 Cells/mL | Participants with R/R AML received IV infusion of ASP7517 (HEK293 transfected with encoding target WT-1) at a dose of 1x10^8 cells/mL at 4 to 6 mL/minute infusion rate on day 1 of each cycle for 6 doses (1 cycle= 28 days). |
| OG004 | Dose Expansion (Phase 2: MDS): ASP7517 1x10^8 Cells/mL | Participants with R/R higher risk MDS received IV infusion of ASP7517 (HEK293 transfected with encoding target WT-1) at a dose of 1x10^8 cells/mL at 4 to 6 mL/minute infusion rate on day 1 of each cycle for 6 doses (1 cycle= 28 days). |
|
|
| OG002 | Dose Escalation (Phase 1): ASP7517 1x10^8 Cells/mL | Participants with R/R AML and R/R higher risk MDS received IV infusion of ASP7517 (HEK293 transfected with encoding target WT-1) at a dose of 1x10^8 cells/mL at 4 to 6 mL/minute infusion rate on day 1 of each cycle for 2 doses (1 cycle= 28 days). |
| OG003 | Dose Expansion (Phase 2: AML): ASP7517 1x10^8 Cells/mL | Participants with R/R AML received IV infusion of ASP7517 (HEK293 transfected with encoding target WT-1) at a dose of 1x10^8 cells/mL at 4 to 6 mL/minute infusion rate on day 1 of each cycle for 6 doses (1 cycle= 28 days). |
| OG004 | Dose Expansion (Phase 2: MDS): ASP7517 1x10^8 Cells/mL | Participants with R/R higher risk MDS received IV infusion of ASP7517 (HEK293 transfected with encoding target WT-1) at a dose of 1x10^8 cells/mL at 4 to 6 mL/minute infusion rate on day 1 of each cycle for 6 doses (1 cycle= 28 days). |
|
|
| OG002 | Dose Escalation (Phase 1): ASP7517 1x10^8 Cells/mL | Participants with R/R AML and R/R higher risk MDS received IV infusion of ASP7517 (HEK293 transfected with encoding target WT-1) at a dose of 1x10^8 cells/mL at 4 to 6 mL/minute infusion rate on day 1 of each cycle for 2 doses (1 cycle= 28 days). |
| OG003 | Dose Expansion (Phase 2: AML): ASP7517 1x10^8 Cells/mL | Participants with R/R AML received IV infusion of ASP7517 (HEK293 transfected with encoding target WT-1) at a dose of 1x10^8 cells/mL at 4 to 6 mL/minute infusion rate on day 1 of each cycle for 6 doses (1 cycle= 28 days). |
| OG004 | Dose Expansion (Phase 2: MDS): ASP7517 1x10^8 Cells/mL | Participants with R/R higher risk MDS received IV infusion of ASP7517 (HEK293 transfected with encoding target WT-1) at a dose of 1x10^8 cells/mL at 4 to 6 mL/minute infusion rate on day 1 of each cycle for 6 doses (1 cycle= 28 days). |
|
|
| OG002 | Dose Escalation (Phase 1): ASP7517 1x10^8 Cells/mL | Participants with R/R AML and R/R higher risk MDS received IV infusion of ASP7517 (HEK293 transfected with encoding target WT-1) at a dose of 1x10^8 cells/mL at 4 to 6 mL/minute infusion rate on day 1 of each cycle for 2 doses (1 cycle= 28 days). |
| OG003 | Dose Expansion (Phase 2: AML): ASP7517 1x10^8 Cells/mL | Participants with R/R AML received IV infusion of ASP7517 (HEK293 transfected with encoding target WT-1) at a dose of 1x10^8 cells/mL at 4 to 6 mL/minute infusion rate on day 1 of each cycle for 6 doses (1 cycle= 28 days). |
| OG004 | Dose Expansion (Phase 2: MDS): ASP7517 1x10^8 Cells/mL | Participants with R/R higher risk MDS received IV infusion of ASP7517 (HEK293 transfected with encoding target WT-1) at a dose of 1x10^8 cells/mL at 4 to 6 mL/minute infusion rate on day 1 of each cycle for 6 doses (1 cycle= 28 days). |
|
|
| OG002 | Dose Escalation (Phase 1): ASP7517 1x10^8 Cells/mL | Participants with R/R AML and R/R higher risk MDS received IV infusion of ASP7517 (HEK293 transfected with encoding target WT-1) at a dose of 1x10^8 cells/mL at 4 to 6 mL/minute infusion rate on day 1 of each cycle for 2 doses (1 cycle= 28 days). |
| OG003 | Dose Expansion (Phase 2: AML): ASP7517 1x10^8 Cells/mL | Participants with R/R AML received IV infusion of ASP7517 (HEK293 transfected with encoding target WT-1) at a dose of 1x10^8 cells/mL at 4 to 6 mL/minute infusion rate on day 1 of each cycle for 6 doses (1 cycle= 28 days). |
| OG004 | Dose Expansion (Phase 2: MDS): ASP7517 1x10^8 Cells/mL | Participants with R/R higher risk MDS received IV infusion of ASP7517 (HEK293 transfected with encoding target WT-1) at a dose of 1x10^8 cells/mL at 4 to 6 mL/minute infusion rate on day 1 of each cycle for 6 doses (1 cycle= 28 days). |
|
|
| OG002 | Dose Escalation (Phase 1): ASP7517 1x10^8 Cells/mL | Participants with R/R AML and R/R higher risk MDS received IV infusion of ASP7517 (HEK293 transfected with encoding target WT-1) at a dose of 1x10^8 cells/mL at 4 to 6 mL/minute infusion rate on day 1 of each cycle for 2 doses (1 cycle= 28 days). |
| OG003 | Dose Expansion (Phase 2: AML): ASP7517 1x10^8 Cells/mL | Participants with R/R AML received IV infusion of ASP7517 (HEK293 transfected with encoding target WT-1) at a dose of 1x10^8 cells/mL at 4 to 6 mL/minute infusion rate on day 1 of each cycle for 6 doses (1 cycle= 28 days). |
| OG004 | Dose Expansion (Phase 2: MDS): ASP7517 1x10^8 Cells/mL | Participants with R/R higher risk MDS received IV infusion of ASP7517 (HEK293 transfected with encoding target WT-1) at a dose of 1x10^8 cells/mL at 4 to 6 mL/minute infusion rate on day 1 of each cycle for 6 doses (1 cycle= 28 days). |
|
|
| OG002 | Dose Escalation (Phase 1): ASP7517 1x10^8 Cells/mL | Participants with R/R AML and R/R higher risk MDS received IV infusion of ASP7517 (HEK293 transfected with encoding target WT-1) at a dose of 1x10^8 cells/mL at 4 to 6 mL/minute infusion rate on day 1 of each cycle for 2 doses (1 cycle= 28 days). |
| OG003 | Dose Expansion (Phase 2: AML): ASP7517 1x10^8 Cells/mL | Participants with R/R AML received IV infusion of ASP7517 (HEK293 transfected with encoding target WT-1) at a dose of 1x10^8 cells/mL at 4 to 6 mL/minute infusion rate on day 1 of each cycle for 6 doses (1 cycle= 28 days). |
| OG004 | Dose Expansion (Phase 2: MDS): ASP7517 1x10^8 Cells/mL | Participants with R/R higher risk MDS received IV infusion of ASP7517 (HEK293 transfected with encoding target WT-1) at a dose of 1x10^8 cells/mL at 4 to 6 mL/minute infusion rate on day 1 of each cycle for 6 doses (1 cycle= 28 days). |
|
|
| OG002 | Dose Escalation (Phase 1): ASP7517 1x10^8 Cells/mL | Participants with R/R AML and R/R higher risk MDS received IV infusion of ASP7517 (HEK293 transfected with encoding target WT-1) at a dose of 1x10^8 cells/mL at 4 to 6 mL/minute infusion rate on day 1 of each cycle for 2 doses (1 cycle= 28 days). |
| OG003 | Dose Expansion (Phase 2: AML): ASP7517 1x10^8 Cells/mL | Participants with R/R AML received IV infusion of ASP7517 (HEK293 transfected with encoding target WT-1) at a dose of 1x10^8 cells/mL at 4 to 6 mL/minute infusion rate on day 1 of each cycle for 6 doses (1 cycle= 28 days). |
| OG004 | Dose Expansion (Phase 2: MDS): ASP7517 1x10^8 Cells/mL | Participants with R/R higher risk MDS received IV infusion of ASP7517 (HEK293 transfected with encoding target WT-1) at a dose of 1x10^8 cells/mL at 4 to 6 mL/minute infusion rate on day 1 of each cycle for 6 doses (1 cycle= 28 days). |
|
|
| OG002 | Dose Escalation (Phase 1): ASP7517 1x10^8 Cells/mL | Participants with R/R AML and R/R higher risk MDS received IV infusion of ASP7517 (HEK293 transfected with encoding target WT-1) at a dose of 1x10^8 cells/mL at 4 to 6 mL/minute infusion rate on day 1 of each cycle for 2 doses (1 cycle= 28 days). |
| OG003 | Dose Expansion (Phase 2: AML): ASP7517 1x10^8 Cells/mL | Participants with R/R AML received IV infusion of ASP7517 (HEK293 transfected with encoding target WT-1) at a dose of 1x10^8 cells/mL at 4 to 6 mL/minute infusion rate on day 1 of each cycle for 6 doses (1 cycle= 28 days). |
| OG004 | Dose Expansion (Phase 2: MDS): ASP7517 1x10^8 Cells/mL | Participants with R/R higher risk MDS received IV infusion of ASP7517 (HEK293 transfected with encoding target WT-1) at a dose of 1x10^8 cells/mL at 4 to 6 mL/minute infusion rate on day 1 of each cycle for 6 doses (1 cycle= 28 days). |
|
|
| OG002 | Dose Escalation (Phase 1): ASP7517 1x10^8 Cells/mL | Participants with R/R AML and R/R higher risk MDS received IV infusion of ASP7517 (HEK293 transfected with encoding target WT-1) at a dose of 1x10^8 cells/mL at 4 to 6 mL/minute infusion rate on day 1 of each cycle for 2 doses (1 cycle= 28 days). |
| OG003 | Dose Expansion (Phase 2: AML): ASP7517 1x10^8 Cells/mL | Participants with R/R AML received IV infusion of ASP7517 (HEK293 transfected with encoding target WT-1) at a dose of 1x10^8 cells/mL at 4 to 6 mL/minute infusion rate on day 1 of each cycle for 6 doses (1 cycle= 28 days). |
| OG004 | Dose Expansion (Phase 2: MDS): ASP7517 1x10^8 Cells/mL | Participants with R/R higher risk MDS received IV infusion of ASP7517 (HEK293 transfected with encoding target WT-1) at a dose of 1x10^8 cells/mL at 4 to 6 mL/minute infusion rate on day 1 of each cycle for 6 doses (1 cycle= 28 days). |
|
|
| OG002 | Dose Escalation (Phase 1): ASP7517 1x10^8 Cells/mL | Participants with R/R AML and R/R higher risk MDS received IV infusion of ASP7517 (HEK293 transfected with encoding target WT-1) at a dose of 1x10^8 cells/mL at 4 to 6 mL/minute infusion rate on day 1 of each cycle for 2 doses (1 cycle= 28 days). |
| OG003 | Dose Expansion (Phase 2: AML): ASP7517 1x10^8 Cells/mL | Participants with R/R AML received IV infusion of ASP7517 (HEK293 transfected with encoding target WT-1) at a dose of 1x10^8 cells/mL at 4 to 6 mL/minute infusion rate on day 1 of each cycle for 6 doses (1 cycle= 28 days). |
| OG004 | Dose Expansion (Phase 2: MDS): ASP7517 1x10^8 Cells/mL | Participants with R/R higher risk MDS received IV infusion of ASP7517 (HEK293 transfected with encoding target WT-1) at a dose of 1x10^8 cells/mL at 4 to 6 mL/minute infusion rate on day 1 of each cycle for 6 doses (1 cycle= 28 days). |
|
|
| OG002 | Dose Escalation (Phase 1): ASP7517 1x10^8 Cells/mL | Participants with R/R AML and R/R higher risk MDS received IV infusion of ASP7517 (HEK293 transfected with encoding target WT-1) at a dose of 1x10^8 cells/mL at 4 to 6 mL/minute infusion rate on day 1 of each cycle for 2 doses (1 cycle= 28 days). |
| OG003 | Dose Expansion (Phase 2: AML): ASP7517 1x10^8 Cells/mL | Participants with R/R AML received IV infusion of ASP7517 (HEK293 transfected with encoding target WT-1) at a dose of 1x10^8 cells/mL at 4 to 6 mL/minute infusion rate on day 1 of each cycle for 6 doses (1 cycle= 28 days). |
| OG004 | Dose Expansion (Phase 2: MDS): ASP7517 1x10^8 Cells/mL | Participants with R/R higher risk MDS received IV infusion of ASP7517 (HEK293 transfected with encoding target WT-1) at a dose of 1x10^8 cells/mL at 4 to 6 mL/minute infusion rate on day 1 of each cycle for 6 doses (1 cycle= 28 days). |
|
|
| OG002 | Dose Escalation (Phase 1): ASP7517 1x10^8 Cells/mL | Participants with R/R AML and R/R higher risk MDS received IV infusion of ASP7517 (HEK293 transfected with encoding target WT-1) at a dose of 1x10^8 cells/mL at 4 to 6 mL/minute infusion rate on day 1 of each cycle for 2 doses (1 cycle= 28 days). |
| OG003 | Dose Expansion (Phase 2: AML): ASP7517 1x10^8 Cells/mL | Participants with R/R AML received IV infusion of ASP7517 (HEK293 transfected with encoding target WT-1) at a dose of 1x10^8 cells/mL at 4 to 6 mL/minute infusion rate on day 1 of each cycle for 6 doses (1 cycle= 28 days). |
| OG004 | Dose Expansion (Phase 2: MDS): ASP7517 1x10^8 Cells/mL | Participants with R/R higher risk MDS received IV infusion of ASP7517 (HEK293 transfected with encoding target WT-1) at a dose of 1x10^8 cells/mL at 4 to 6 mL/minute infusion rate on day 1 of each cycle for 6 doses (1 cycle= 28 days). |
|
|
| OG002 | Dose Escalation (Phase 1): ASP7517 1x10^8 Cells/mL | Participants with R/R AML and R/R higher risk MDS received IV infusion of ASP7517 (HEK293 transfected with encoding target WT-1) at a dose of 1x10^8 cells/mL at 4 to 6 mL/minute infusion rate on day 1 of each cycle for 2 doses (1 cycle= 28 days). |
| OG003 | Dose Expansion (Phase 2: AML): ASP7517 1x10^8 Cells/mL | Participants with R/R AML received IV infusion of ASP7517 (HEK293 transfected with encoding target WT-1) at a dose of 1x10^8 cells/mL at 4 to 6 mL/minute infusion rate on day 1 of each cycle for 6 doses (1 cycle= 28 days). |
| OG004 | Dose Expansion (Phase 2: MDS): ASP7517 1x10^8 Cells/mL | Participants with R/R higher risk MDS received IV infusion of ASP7517 (HEK293 transfected with encoding target WT-1) at a dose of 1x10^8 cells/mL at 4 to 6 mL/minute infusion rate on day 1 of each cycle for 6 doses (1 cycle= 28 days). |
|
|
| OG002 | Dose Escalation (Phase 1): ASP7517 1x10^8 Cells/mL | Participants with R/R AML and R/R higher risk MDS received IV infusion of ASP7517 (HEK293 transfected with encoding target WT-1) at a dose of 1x10^8 cells/mL at 4 to 6 mL/minute infusion rate on day 1 of each cycle for 2 doses (1 cycle= 28 days). |
| OG003 | Dose Expansion (Phase 2: AML): ASP7517 1x10^8 Cells/mL | Participants with R/R AML received IV infusion of ASP7517 (HEK293 transfected with encoding target WT-1) at a dose of 1x10^8 cells/mL at 4 to 6 mL/minute infusion rate on day 1 of each cycle for 6 doses (1 cycle= 28 days). |
| OG004 | Dose Expansion (Phase 2: MDS): ASP7517 1x10^8 Cells/mL | Participants with R/R higher risk MDS received IV infusion of ASP7517 (HEK293 transfected with encoding target WT-1) at a dose of 1x10^8 cells/mL at 4 to 6 mL/minute infusion rate on day 1 of each cycle for 6 doses (1 cycle= 28 days). |
|
|
| OG002 | Dose Escalation (Phase 1): ASP7517 1x10^8 Cells/mL | Participants with R/R AML and R/R higher risk MDS received IV infusion of ASP7517 (HEK293 transfected with encoding target WT-1) at a dose of 1x10^8 cells/mL at 4 to 6 mL/minute infusion rate on day 1 of each cycle for 2 doses (1 cycle= 28 days). |
| OG003 | Dose Expansion (Phase 2: AML): ASP7517 1x10^8 Cells/mL | Participants with R/R AML received IV infusion of ASP7517 (HEK293 transfected with encoding target WT-1) at a dose of 1x10^8 cells/mL at 4 to 6 mL/minute infusion rate on day 1 of each cycle for 6 doses (1 cycle= 28 days). |
| OG004 | Dose Expansion (Phase 2: MDS): ASP7517 1x10^8 Cells/mL | Participants with R/R higher risk MDS received IV infusion of ASP7517 (HEK293 transfected with encoding target WT-1) at a dose of 1x10^8 cells/mL at 4 to 6 mL/minute infusion rate on day 1 of each cycle for 6 doses (1 cycle= 28 days). |
|
|
| OG002 | Dose Escalation (Phase 1): ASP7517 1x10^8 Cells/mL | Participants with R/R AML and R/R higher risk MDS received IV infusion of ASP7517 (HEK293 transfected with encoding target WT-1) at a dose of 1x10^8 cells/mL at 4 to 6 mL/minute infusion rate on day 1 of each cycle for 2 doses (1 cycle= 28 days). |
|
|
|
|
| OG002 | Dose Escalation (Phase 1): ASP7517 1x10^8 Cells/mL | Participants with R/R AML and R/R higher risk MDS received IV infusion of ASP7517 (HEK293 transfected with encoding target WT-1) at a dose of 1x10^8 cells/mL at 4 to 6 mL/minute infusion rate on day 1 of each cycle for 2 doses (1 cycle= 28 days). |
| OG003 | Dose Expansion (Phase 2: AML): ASP7517 1x10^8 Cells/mL | Participants with R/R AML received IV infusion of ASP7517 (HEK293 transfected with encoding target WT-1) at a dose of 1x10^8 cells/mL at 4 to 6 mL/minute infusion rate on day 1 of each cycle for 6 doses (1 cycle= 28 days). |
| OG004 | Dose Expansion (Phase 2: MDS): ASP7517 1x10^8 Cells/mL | Participants with R/R higher risk MDS received IV infusion of ASP7517 (HEK293 transfected with encoding target WT-1) at a dose of 1x10^8 cells/mL at 4 to 6 mL/minute infusion rate on day 1 of each cycle for 6 doses (1 cycle= 28 days). |
|
|
| OG002 | Dose Escalation (Phase 1): ASP7517 1x10^8 Cells/mL | Participants with R/R AML and R/R higher risk MDS received IV infusion of ASP7517 (HEK293 transfected with encoding target WT-1) at a dose of 1x10^8 cells/mL at 4 to 6 mL/minute infusion rate on day 1 of each cycle for 2 doses (1 cycle= 28 days). |
| OG003 | Dose Expansion (Phase 2: AML): ASP7517 1x10^8 Cells/mL | Participants with R/R AML received IV infusion of ASP7517 (HEK293 transfected with encoding target WT-1) at a dose of 1x10^8 cells/mL at 4 to 6 mL/minute infusion rate on day 1 of each cycle for 6 doses (1 cycle= 28 days). |
| OG004 | Dose Expansion (Phase 2: MDS): ASP7517 1x10^8 Cells/mL | Participants with R/R higher risk MDS received IV infusion of ASP7517 (HEK293 transfected with encoding target WT-1) at a dose of 1x10^8 cells/mL at 4 to 6 mL/minute infusion rate on day 1 of each cycle for 6 doses (1 cycle= 28 days). |
|
|
| OG002 | Dose Escalation (Phase 1): ASP7517 1x10^8 Cells/mL | Participants with R/R AML and R/R higher risk MDS received IV infusion of ASP7517 (HEK293 transfected with encoding target WT-1) at a dose of 1x10^8 cells/mL at 4 to 6 mL/minute infusion rate on day 1 of each cycle for 2 doses (1 cycle= 28 days). |
| OG003 | Dose Expansion (Phase 2: AML): ASP7517 1x10^8 Cells/mL | Participants with R/R AML received IV infusion of ASP7517 (HEK293 transfected with encoding target WT-1) at a dose of 1x10^8 cells/mL at 4 to 6 mL/minute infusion rate on day 1 of each cycle for 6 doses (1 cycle= 28 days). |
| OG004 | Dose Expansion (Phase 2: MDS): ASP7517 1x10^8 Cells/mL | Participants with R/R higher risk MDS received IV infusion of ASP7517 (HEK293 transfected with encoding target WT-1) at a dose of 1x10^8 cells/mL at 4 to 6 mL/minute infusion rate on day 1 of each cycle for 6 doses (1 cycle= 28 days). |
|
|
| OG002 | Dose Escalation (Phase 1): ASP7517 1x10^8 Cells/mL | Participants with R/R AML and R/R higher risk MDS received IV infusion of ASP7517 (HEK293 transfected with encoding target WT-1) at a dose of 1x10^8 cells/mL at 4 to 6 mL/minute infusion rate on day 1 of each cycle for 2 doses (1 cycle= 28 days). |
| OG003 | Dose Expansion (Phase 2: AML): ASP7517 1x10^8 Cells/mL | Participants with R/R AML received IV infusion of ASP7517 (HEK293 transfected with encoding target WT-1) at a dose of 1x10^8 cells/mL at 4 to 6 mL/minute infusion rate on day 1 of each cycle for 6 doses (1 cycle= 28 days). |
| OG004 | Dose Expansion (Phase 2: MDS): ASP7517 1x10^8 Cells/mL | Participants with R/R higher risk MDS received IV infusion of ASP7517 (HEK293 transfected with encoding target WT-1) at a dose of 1x10^8 cells/mL at 4 to 6 mL/minute infusion rate on day 1 of each cycle for 6 doses (1 cycle= 28 days). |
|
|
| OG002 | Dose Escalation (Phase 1): ASP7517 1x10^8 Cells/mL | Participants with R/R AML and R/R higher risk MDS received IV infusion of ASP7517 (HEK293 transfected with encoding target WT-1) at a dose of 1x10^8 cells/mL at 4 to 6 mL/minute infusion rate on day 1 of each cycle for 2 doses (1 cycle= 28 days). |
| OG003 | Dose Expansion (Phase 2: AML): ASP7517 1x10^8 Cells/mL | Participants with R/R AML received IV infusion of ASP7517 (HEK293 transfected with encoding target WT-1) at a dose of 1x10^8 cells/mL at 4 to 6 mL/minute infusion rate on day 1 of each cycle for 6 doses (1 cycle= 28 days). |
| OG004 | Dose Expansion (Phase 2: MDS): ASP7517 1x10^8 Cells/mL | Participants with R/R higher risk MDS received IV infusion of ASP7517 (HEK293 transfected with encoding target WT-1) at a dose of 1x10^8 cells/mL at 4 to 6 mL/minute infusion rate on day 1 of each cycle for 6 doses (1 cycle= 28 days). |
|
|
| OG002 | Dose Escalation (Phase 1): ASP7517 1x10^8 Cells/mL | Participants with R/R AML and R/R higher risk MDS received IV infusion of ASP7517 (HEK293 transfected with encoding target WT-1) at a dose of 1x10^8 cells/mL at 4 to 6 mL/minute infusion rate on day 1 of each cycle for 2 doses (1 cycle= 28 days). |
| OG003 | Dose Expansion (Phase 2: AML): ASP7517 1x10^8 Cells/mL | Participants with R/R AML received IV infusion of ASP7517 (HEK293 transfected with encoding target WT-1) at a dose of 1x10^8 cells/mL at 4 to 6 mL/minute infusion rate on day 1 of each cycle for 6 doses (1 cycle= 28 days). |
| OG004 | Dose Expansion (Phase 2: MDS): ASP7517 1x10^8 Cells/mL | Participants with R/R higher risk MDS received IV infusion of ASP7517 (HEK293 transfected with encoding target WT-1) at a dose of 1x10^8 cells/mL at 4 to 6 mL/minute infusion rate on day 1 of each cycle for 6 doses (1 cycle= 28 days). |
|
|
| OG001 | Dose Escalation (Phase 1) (AML): ASP7517 1x10^7 Cells/mL | Participants with R/R AML received IV infusion of ASP7517 (HEK293 transfected with encoding target WT-1) at a dose of 1x10^7 cells/mL at 4 to 6 mL/minute infusion rate on day 1 of each cycle for 2 doses (1 cycle= 28 days). |
| OG002 | Dose Escalation and Expansion Phase (AML): ASP7517 1x10^8 Cells/mL | Participants with R/R AML received IV infusion of ASP7517 (HEK293 transfected with encoding target WT-1) at a dose of 1x10^8 cells/mL at 4 to 6 mL/minute infusion rate on day 1 of each cycle (escalation phase: 2 doses and expansion phase: 6 doses) (1 cycle= 28 days). |
|
|
| OG002 | Dose Escalation and Expansion Phase (MDS): ASP7517 1x10^8 Cells/mL | Participants with R/R higher risk MDS received IV infusion of ASP7517 (HEK293 transfected with encoding target WT-1) at a dose of 1x10^8 cells/mL at 4 to 6 mL/minute infusion rate on day 1 of each cycle (escalation phase: 2 doses and expansion phase: 6 doses) (1 cycle= 28 days). |
|
|
Participants with R/R AML received IV infusion of ASP7517 (HEK293 transfected with encoding target WT-1) at a dose of 1x10^7 cells/mL at 4 to 6 mL/minute infusion rate on day 1 of each cycle for 2 doses (1 cycle= 28 days). |
| OG002 | Dose Escalation and Expansion Phase (AML): ASP7517 1x10^8 Cells/mL | Participants with R/R AML received IV infusion of ASP7517 (HEK293 transfected with encoding target WT-1) at a dose of 1x10^8 cells/mL at 4 to 6 mL/minute infusion rate on day 1 of each cycle (escalation phase: 2 doses and expansion phase: 6 doses) (1 cycle= 28 days). |
| OG003 | Dose Escalation (Phase 1) (MDS): ASP7517 1x10^6 Cells/m | Participants with R/R higher risk MDS received IV infusion of ASP7517 (HEK293 transfected with encoding target WT-1) at a dose of 1x10^6 cells/mL at 4 to 6 mL/minute infusion rate on day 1 of each cycle for 2 doses (1 cycle= 28 days). |
| OG004 | Dose Escalation (Phase 1) (MDS): ASP7517 1x10^7 Cells/mL | Participants with R/R higher risk MDS received IV infusion of ASP7517 (HEK293 transfected with encoding target WT-1) at a dose of 1x10^7 cells/mL at 4 to 6 mL/minute infusion rate on day 1 of each cycle for 2 doses (1 cycle= 28 days). |
| OG005 | Dose Escalation and Expansion (MDS): ASP7517 1x10^8 Cells/mL | Participants with R/R higher risk MDS received IV infusion of ASP7517 (HEK293 transfected with encoding target WT-1) at a dose of 1x10^8 cells/mL at 4 to 6 mL/minute infusion rate on day 1 of each cycle (escalation phase: 2 doses and expansion phase: 6 doses) (1 cycle= 28 days). |
|
|
| Dose Escalation and Expansion Phase (AML): ASP7517 1x10^8 Cells/mL |
Participants with R/R AML received IV infusion of ASP7517 (HEK293 transfected with encoding target WT-1) at a dose of 1x10^8 cells/mL at 4 to 6 mL/minute infusion rate on day 1 of each cycle (escalation phase: 2 doses and expansion phase: 6 doses) (1 cycle= 28 days). |
| OG003 | Dose Escalation (Phase 1) (MDS): ASP7517 1x10^6 Cells/mL | Participants with R/R higher risk MDS received IV infusion of ASP7517 (HEK293 transfected with encoding target WT-1) at a dose of 1x10^6 cells/mL at 4 to 6 mL/minute infusion rate on day 1 of each cycle for 2 doses (1 cycle= 28 days). |
| OG004 | Dose Escalation (Phase 1) (MDS): ASP7517 1x10^7 Cells/mL | Participants with R/R higher risk MDS received IV infusion of ASP7517 (HEK293 transfected with encoding target WT-1) at a dose of 1x10^7 cells/mL at 4 to 6 mL/minute infusion rate on day 1 of each cycle for 2 doses (1 cycle= 28 days). |
| OG005 | Dose Escalation and Expansion Phase (MDS): ASP7517 1x10^8 Cells/mL | Participants with R/R higher risk MDS received IV infusion of ASP7517 (HEK293 transfected with encoding target WT-1) at a dose of 1x10^8 cells/mL at 4 to 6 mL/minute infusion rate on day 1 of each cycle (escalation phase: 2 doses and expansion phase: 6 doses) (1 cycle= 28 days). |
|
|
| Dose Escalation (Phase 1) (AML): ASP7517 1x10^8 Cells/mL |
Participants with R/R AML received IV infusion of ASP7517 (HEK293 transfected with encoding target WT-1) at a dose of 1x10^8 cells/mL at 4 to 6 mL/minute infusion rate on day 1 of each cycle for 2 doses (1 cycle= 28 days). |
| OG003 | Dose Expansion (Phase 2) (AML): ASP7517 1x10^8 Cells/mL | Participants with R/R AML received IV infusion of ASP7517 (HEK293 transfected with encoding target WT-1) at a dose of 1x10^8 cells/mL at 4 to 6 mL/minute infusion rate on day 1 of each cycle for 6 doses (1 cycle= 28 days). |
|
|
| OG002 | Dose Escalation (Phase 1) (AML): ASP7517 1x10^8 Cells/mL | Participants with R/R AML received IV infusion of ASP7517 (HEK293 transfected with encoding target WT-1) at a dose of 1x10^8 cells/mL at 4 to 6 mL/minute infusion rate on day 1 of each cycle for 2 doses (1 cycle= 28 days). |
| OG003 | Dose Expansion (Phase 2) (AML): ASP7517 1x10^8 Cells/mL | Participants with R/R AML received IV infusion of ASP7517 (HEK293 transfected with encoding target WT-1) at a dose of 1x10^8 cells/mL at 4 to 6 mL/minute infusion rate on day 1 of each cycle for 6 doses (1 cycle= 28 days). |
|
|
| OG003 | Dose Expansion (Phase 2) (AML): ASP7517 1x10^8 Cells/mL | Participants with R/R AML received IV infusion of ASP7517 (HEK293 transfected with encoding target WT-1) at a dose of 1x10^8 cells/mL at 4 to 6 mL/minute infusion rate on day 1 of each cycle for 6 doses (1 cycle= 28 days). |
|
|
| OG003 | Dose Expansion (Phase 2) (MDS): ASP7517 1x10^8 Cells/mL | Participants with R/R higher risk MDS received IV infusion of ASP7517 (HEK293 transfected with encoding target WT-1) at a dose of 1x10^8 cells/mL at 4 to 6 mL/minute infusion rate on day 1 of each cycle for 6 doses (1 cycle= 28 days). |
|
|
| Dose Escalation (Phase 1) (MDS): ASP7517 1x10^8 Cells/mL |
Participants with R/R higher risk MDS received IV infusion of ASP7517 (HEK293 transfected with encoding target WT-1) at a dose of 1x10^8 cells/mL at 4 to 6 mL/minute infusion rate on day 1 of each cycle for 2 doses (1 cycle= 28 days). |
| OG003 | Dose Expansion (Phase 2) (MDS): ASP7517 1x10^8 Cells/mL | Participants with R/R higher risk MDS received IV infusion of ASP7517 (HEK293 transfected with encoding target WT-1) at a dose of 1x10^8 cells/mL at 4 to 6 mL/minute infusion rate on day 1 of each cycle for 6 doses (1 cycle= 28 days). |
|
|
| Dose Escalation (Phase 1) (MDS): ASP7517 1x10^7 Cells/mL |
Participants with R/R higher risk MDS received IV infusion of ASP7517 (HEK293 transfected with encoding target WT-1) at a dose of 1x10^7 cells/mL at 4 to 6 mL/minute infusion rate on day 1 of each cycle for 2 doses (1 cycle= 28 days). |
| OG002 | Dose Escalation (Phase 1) (MDS): ASP7517 1x10^8 Cells/mL | Participants with R/R higher risk MDS received IV infusion of ASP7517 (HEK293 transfected with encoding target WT-1) at a dose of 1x10^8 cells/mL at 4 to 6 mL/minute infusion rate on day 1 of each cycle for 2 doses (1 cycle= 28 days). |
| OG003 | Dose Expansion (Phase 2) (MDS): ASP7517 1x10^8 Cells/mL | Participants with R/R higher risk MDS received IV infusion of ASP7517 (HEK293 transfected with encoding target WT-1) at a dose of 1x10^8 cells/mL at 4 to 6 mL/minute infusion rate on day 1 of each cycle for 6 doses (1 cycle= 28 days). |
|
|